<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Opioids for neuropathic pain - McNicol, ED - 2013 | Cochrane Library</title> <meta content="Opioids for neuropathic pain - McNicol, ED - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006146.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Opioids for neuropathic pain - McNicol, ED - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006146.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006146.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Opioids for neuropathic pain" name="citation_title"/> <meta content="Ewan D McNicol" name="citation_author"/> <meta content="Tufts Medical Center" name="citation_author_institution"/> <meta content="ewan.mcnicol@mcphs.edu" name="citation_author_email"/> <meta content="Ayelet Midbari" name="citation_author"/> <meta content="Institute of Pain Medicine" name="citation_author_institution"/> <meta content="Elon Eisenberg" name="citation_author"/> <meta content="Rambam Health Care Campus and the Technion‐Israel Institute of Technology" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD006146.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/08/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006146.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006146.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006146.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics, Opioid [adverse effects, *therapeutic use]; Nervous System Diseases [complications, *drug therapy]; Neuralgia [*drug therapy]; Pain [*drug therapy, etiology]; Pain Measurement [methods, statistics &amp; numerical data]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006146.pub2&amp;doi=10.1002/14651858.CD006146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="kKvAiZoF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006146\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006146\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006146.pub2",title:"Opioids for neuropathic pain",firstPublishedDate:"Aug 29, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006146.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006146.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006146.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006146.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006146.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006146.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006146.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006146.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006146.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006146.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6106 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006146.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/full#CD006146-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/full#CD006146-sec-0089"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/full#CD006146-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/full#CD006146-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/full#CD006146-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/full#CD006146-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/full#CD006146-sec-0077"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/appendices#CD006146-sec-0094"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/table_n/CD006146StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/table_n/CD006146StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Opioids for neuropathic pain</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/information#CD006146-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Ewan D McNicol</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/information#CD006146-cr-0003">Ayelet Midbari</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006146.pub2/information#CD006146-cr-0004">Elon Eisenberg</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/information/en#CD006146-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 August 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006146.pub2">https://doi.org/10.1002/14651858.CD006146.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006146-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006146-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006146-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006146-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006146-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006146-abs-0001" lang="en"> <section id="CD006146-sec-0001"> <h3 class="title" id="CD006146-sec-0001">Background</h3> <p>This is an updated version of the original Cochrane review published in Issue 3, 2006, which included 23 trials. The use of opioids for neuropathic pain remains controversial. Studies have been small, have yielded equivocal results, and have not established the long‐term profile of benefits and risks for people with neuropathic pain. </p> </section> <section id="CD006146-sec-0002"> <h3 class="title" id="CD006146-sec-0002">Objectives</h3> <p>To reassess the efficacy and safety of opioid agonists for the treatment of neuropathic pain. </p> </section> <section id="CD006146-sec-0003"> <h3 class="title" id="CD006146-sec-0003">Search methods</h3> <p>We searched CENTRAL, on <i>The Cochrane Library</i> (Issue 10 of 12, 2012), MEDLINE (1966 to Oct week 3, 2012), and EMBASE (1980 to 2012, week 42) for articles in any language, and reference lists of reviews and retrieved articles. Searches were originally run in 2005, then again in 2010 and 2012. </p> </section> <section id="CD006146-sec-0004"> <h3 class="title" id="CD006146-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) in which opioid agonists were given to treat central or peripheral neuropathic pain of any etiology. Pain was assessed using validated instruments, and adverse events were reported. We excluded studies in which drugs other than opioid agonists were combined with opioids or opioids were administered epidurally or intrathecally. </p> </section> <section id="CD006146-sec-0005"> <h3 class="title" id="CD006146-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and included demographic variables, diagnoses, interventions, efficacy, and adverse effects. </p> </section> <section id="CD006146-sec-0006"> <h3 class="title" id="CD006146-sec-0006">Main results</h3> <p>Thirty‐one trials met our inclusion criteria, studying 10 different opioids: 23 studies from the original 2006 review and eight additional studies from this updated review. </p> <p>Seventeen studies (392 participants with neuropathic pain, average 22 participants per study) provided efficacy data for acute exposure to opioids over less than 24 hours. Sixteen reported pain outcomes, with contradictory results; 8/16 reported less pain with opioids than placebo, 2/16 reported that some but not all participants benefited, 5/16 reported no difference, and 1/16 reported equivocal results. Six studies with about 170 participants indicated that mean pain scores with opioid were about 15/100 points less than placebo. </p> <p>Fourteen studies (845 participants, average 60 participants per study) were of intermediate duration lasting 12 weeks or less; most studies lasted less than six weeks. Most studies used imputation methods for participant withdrawal known to be associated with considerable bias; none used a method known not to be associated with bias. The evidence, therefore, derives from studies predominantly with features likely to overestimate treatment effects, i.e. small size, short duration, and potentially inadequate handling of dropouts. All demonstrated opioid efficacy for spontaneous neuropathic pain. Meta‐analysis demonstrated at least 33% pain relief in 57% of participants receiving an opioid versus 34% of those receiving placebo. The overall point estimate of risk difference was 0.25 (95% confidence interval (CI) 0.13 to 0.37, P &lt; 0.0001), translating to a number needed to treat for an additional beneficial outcome (NNTB) of 4.0 (95% CI 2.7 to 7.7). When the number of participants achieving at least 50% pain relief was analyzed, the overall point estimate of risk difference between opioids (47%) and placebo (30%) was 0.17 (95% CI 0.02 to 0.33, P = 0.03), translating to an NNTB of 5.9 (3.0 to 50.0). In the updated review, opioids did not demonstrate improvement in many aspects of emotional or physical functioning, as measured by various validated questionnaires. Constipation was the most common adverse event (34% opioid versus 9% placebo: number needed to treat for an additional harmful outcome (NNTH) 4.0; 95% CI 3.0 to 5.6), followed by drowsiness (29% opioid versus 14% placebo: NNTH 7.1; 95% CI 4.0 to 33.3), nausea (27% opioid versus 9% placebo: NNTH 6.3; 95% CI 4.0 to 12.5), dizziness (22% opioid versus 8% placebo: NNTH 7.1; 95% CI 5.6 to 10.0), and vomiting (12% opioid versus 4% placebo: NNTH 12.5; 95% CI 6.7 to 100.0). More participants withdrew from opioid treatment due to adverse events (13%) than from placebo (4%) (NNTH 12.5; 95% CI 8.3 to 25.0). Conversely, more participants receiving placebo withdrew due to lack of efficacy (12%) versus (2%) receiving opioids (NNTH ‐11.1; 95% CI ‐20.0 to ‐8.3). </p> </section> <section id="CD006146-sec-0007"> <h3 class="title" id="CD006146-sec-0007">Authors' conclusions</h3> <p>Since the last version of this review, new studies were found providing additional information. Data were reanalyzed but the results did not alter any of our previously published conclusions. Short‐term studies provide only equivocal evidence regarding the efficacy of opioids in reducing the intensity of neuropathic pain. Intermediate‐term studies demonstrated significant efficacy of opioids over placebo, but these results are likely to be subject to significant bias because of small size, short duration, and potentially inadequate handling of dropouts. Analgesic efficacy of opioids in chronic neuropathic pain is subject to considerable uncertainty.  Reported adverse events of opioids were common but not life‐threatening. Further randomized controlled trials are needed to establish unbiased estimates of long‐term efficacy, safety (including addiction potential), and effects on quality of life. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006146-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006146-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006146-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006146-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006146-abs-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006146-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006146-abs-0002" lang="en"> <h3>Opioids for neuropathic pain</h3> <p>Neuropathic pain is pain caused by nerve damage. It is often difficult to diagnose and treat. The use of opioids (strong pain killers such as morphine) to treat neuropathic pain is controversial owing to concerns about addiction and beliefs that this type of pain does not always respond well to opioids. The review looked at short‐term studies lasting less than a day and intermediate‐term trials lasting from several days to 12 weeks. The 31 studies found involved 1237 people with neuropathic pain; most studies were small. </p> <p>Short‐term studies produced mixed results, with just over half indicating that opioids might be better than a placebo. While intermediate‐term studies all indicated that opioids were better than placebo, most studies were small, most were short, and none used methods known to be unbiased. All these features are likely to make effects of opioids look better in clinical trials than they are in clinical practice. We cannot say whether opioids are better than placebo for neuropathic pain over the long term. Side effects such as constipation, nausea, dizziness, and drowsiness were common, but not life‐threatening. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006146-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006146-sec-0089"></div> <h3 class="title" id="CD006146-sec-0090">Implications for practice</h3> <section id="CD006146-sec-0090"> <p>Short‐term studies provided only equivocal evidence regarding the efficacy of opioids in reducing the intensity of neuropathic pain. Intermediate‐term studies demonstrated significant efficacy of opioids over placebo, but these results are likely to be subject to significant bias because of small size, short duration, and unclear, potentially inadequate methods for handling of dropouts. Analgesic efficacy of opioids in chronic neuropathic pain is subject to considerable uncertainty. The difference in outcomes between short‐term and intermediate‐term opioid studies does not support the use of short‐term opioid administration as a predictive tool to decide whether to initiate a trial of opioid therapy. Although our review demonstrated clinically significant efficacy of opioids and an increase in the incidence of commonly‐reported side effects in the intermediate term for neuropathic pain, the participants in the included studies may not reflect those commonly seen in practice. Therefore, issues such as rare but serious adverse events, abuse of medication, or conversely, non‐compliance due to participants' unwillingness to tolerate side effects may not be accurately reflected in our results. Clinicians may be required to assess persons' suitability for a trial of opioid therapy and to monitor progress more rigorously than they would for other pharmacological treatments. </p> </section> <h3 class="title" id="CD006146-sec-0091">Implications for research</h3> <section id="CD006146-sec-0091"> <p>Our updated and revised meta‐analysis takes the necessary step of showing efficacy for spontaneous pain during opioid treatment for up to three months. A goal of future studies in this area should be to evaluate the true efficacy of opioids for neuropathic pain by means of trials with wider dose ranges rather than fixed‐dose studies. In addition, further RCTs assessing longer‐term efficacy, safety (including addiction potential), and improved quality of life should be undertaken before the value of opioids for management of neuropathic pain is finally established. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006146-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006146-sec-0022"></div> <p>This review is an update of a previously published review in the <i>Cochrane Database of Systematic Reviews</i> (Issue 3, 2006) on 'Opioids for neuropathic pain'. </p> <section id="CD006146-sec-0023"> <h3 class="title" id="CD006146-sec-0023">Description of the condition</h3> <p>The percentage of people suffering from neuropathic pain is unknown, but is estimated to be as high as 7% to 8% (<a href="./references#CD006146-bbs2-0080" title="BouhassiraD , Lanteri‐MinetM . Prevalence of chronic pain with neuropathic characteristics in the general population. Pain2008;136:380‐7. ">Bouhassira 2008</a>; <a href="./references#CD006146-bbs2-0117" title="TorranceN , SmithBH . The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain2006;7:281‐9. ">Torrance 2006</a>) in developed nations. Estimates of the prevalence of chronic pain (of which neuropathic pain is a subset) suggest that around 20% of both developed and undeveloped nations' populations are affected (<a href="./references#CD006146-bbs2-0081" title="BreivikH , BondMJ . Why pain control matters in a world full of killer diseases. www.iasp‐pain.org/PCU04‐4.pdf (accessed 23 August 2005). ">Breivik 2004</a>; <a href="./references#CD006146-bbs2-0082" title="BreivikH , CollettB . Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. European Journal of Pain2006;10:287‐33. ">Breivik 2006</a>). Neuropathic pain may result from a large variety of insults to the peripheral or central somatosensory nervous system, including trauma, inflammation, ischemia, and metabolic and neoplastic disorders. Common examples of peripheral neuropathic pain include diabetic neuropathy and postsurgical neuralgia. Central neuropathic pain includes central post‐stroke pain, pain in multiple sclerosis, and pain after spinal cord injury. The main clinical characteristics of neuropathic pain are continuous or intermittent spontaneous pain, typically described as burning, aching, or shooting in quality, and abnormal sensitivity of the painful site to normally innocuous stimuli such as light touch by garments, running water, or even wind (allodynia) (<a href="./references#CD006146-bbs2-0079" title="BaronR , BinderA . Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurology2010;9:807‐19. ">Baron 2010</a>; <a href="./references#CD006146-bbs2-0098" title="MaierC , BaronR . Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain2010;150:439‐50. ">Maier 2010</a>). Neuropathic pain, like many other forms of chronic pain, often has negative effects on quality of life (<a href="./references#CD006146-bbs2-0097" title="JensenMP , ChodroffMJ . The impact of neuropathic pain on health‐related quality of life: review and implications. Neurology2007;68:1178‐82. ">Jensen 2007</a>; <a href="./references#CD006146-bbs2-0101" title="Meyer‐RosbergK , KvarnströmA . Peripheral neuropathic pain ‐ a multidimensional burden for patients. European Journal of Pain2001;5:379‐89. ">Meyer‐Rosberg 2001</a>). Pharmacotherapy for neuropathic pain has generally involved the use of antidepressants or anticonvulsants, but even with the current generation of these drugs, effective analgesia is achieved in less than half of this population (<a href="./references#CD006146-bbs2-0090" title="DworkinRH , O'ConnorAB . Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clinic Proceedings2010;83:S3‐14. ">Dworkin 2010</a>; <a href="./references#CD006146-bbs2-0092" title="FinnerupNB , SindrupSH , JensenTS . The evidence for pharmacological treatment of neuropathic pain. Pain2010;150:573‐81. ">Finnerup 2010</a>; <a href="./references#CD006146-bbs2-0110" title="O'ConnorAB , DworkinRH . Treatment of neuropathic pain: an overview of recent guidelines. American Journal of Medicine2009;122:S22‐32. ">O'Connor 2009</a>; <a href="./references#CD006146-bbs2-0114" title="SindrupHJ , JensenTS . Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain1999;83:389‐400. ">Sindrup 1999</a>). </p> </section> <section id="CD006146-sec-0024"> <h3 class="title" id="CD006146-sec-0024">Description of the intervention</h3> <p>Opioids are the most effective broad‐spectrum analgesics available and are considered the cornerstone of therapy for moderate‐to‐severe acute pain or pain of similar intensity due to life‐threatening illnesses, but their long‐term use in non‐cancer pain, of which neuropathic pain is a component, is controversial. In the United States, the therapeutic use of opioids in general has risen significantly over the last decade (<a href="./references#CD006146-bbs2-0099" title="ManchikantiL , SinghA . Therapeutic opioids: a ten‐year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician2008;11:S63‐88. ">Manchikanti 2008</a>). Despite this, the safety and efficacy of the different opioids in the treatment of neuropathic pain have yet to be established. Clinical trials assessing the efficacy of opioids for reducing neuropathic pain have been reported for more than 25 years, yet great variability in trial design in terms of the type of neuropathic pain syndrome treated, the type of opioid administered, and the duration of treatment has yielded contradictory results. Studies that have suggested efficacy have used small study populations, raising questions about the validity of the results. </p> </section> <section id="CD006146-sec-0025"> <h3 class="title" id="CD006146-sec-0025">How the intervention might work</h3> <p>Opioids provide analgesia by binding to opioid receptors of the mu and kappa class and blocking the release of neurotransmitters such as substance P. Opioid receptors are expressed both centrally and peripherally during the inflammatory response in injured tissue. </p> </section> <section id="CD006146-sec-0026"> <h3 class="title" id="CD006146-sec-0026">Why it is important to do this review</h3> <p>There is a lack of definitive evidence regarding the efficacy of opioids in reducing neuropathic pain in general, and central neuropathic pain in particular. Equally, there are concerns about tolerability of opioids and the potential for abuse, addiction, hormonal abnormalities, dysfunction of the immune system, and, in some cases, paradoxical hyperalgesia with long‐term use (<a href="./references#CD006146-bbs2-0112" title="RhodinA , StridsbergM . Opioid endocrinopathy: a clinical problem in patients with chronic pain and long‐term oral opioid treatment. Clinical Journal of Pain2010;26:374‐80. ">Rhodin 2010</a>; <a href="./references#CD006146-bbs2-0113" title="SehgalN , ManchikantiL . Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician2012;15:ES67‐92. ">Seghal 2012</a>; <a href="./references#CD006146-bbs2-0116" title="TompkinDA , CampbellCM . Opioid‐induced hyperalgesia: clinically relevant or extraneous research phenomenon?. Current Pain and Headache Reports2011;15:129‐36. ">Tompkin 2011</a>; <a href="./references#CD006146-bbs2-0118" title="VallejoR , DeLeon‐CasasolaO . Opioid therapy and immunosuppression: a review. American Journal of Therapeutics2004;11:354‐65. ">Vallejo 2004</a>). Therefore, we conducted a systematic review of published randomized controlled trials (RCTs). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006146-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006146-sec-0027"></div> <p>We attempted to answer two questions:<br/> 1) What is the efficacy of opioid agonists in relieving neuropathic pain?<br/> 2) What is the nature and incidence or severity of adverse effects caused by opioid agonists in people with neuropathic pain? </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006146-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006146-sec-0028"></div> <section id="CD006146-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006146-sec-0030"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs) in this review if opioid agonists (but not partial agonists or agonist‐antagonists) were given to treat central or peripheral neuropathic pain of any etiology. Studies with pain intensity as the primary or secondary outcome were included. Non‐randomized studies and case reports were excluded, as were retrieved trials that presented insufficient data to allow assessment of the outcomes of interest or study quality. </p> </section> <section id="CD006146-sec-0031"> <h4 class="title">Types of participants</h4> <p>We included men and women of all ages and races or ethnicities. We excluded studies in which participants with both neuropathic and other types of pain (e.g. nociceptive) were enrolled and responses of the two groups were not presented separately. </p> </section> <section id="CD006146-sec-0032"> <h4 class="title">Types of interventions</h4> <p>We included studies in which one or more opioid agonists or different doses of the same opioid agonist were compared with placebo, each other, or another class of medication used for neuropathic pain (e.g. antidepressants). We included studies in which drugs were administered by any of the following routes: oral, rectal, transdermal, intravenous, intramuscular, or subcutaneous. </p> <p>We excluded studies in which: drugs other than opioid agonists were combined with opioids (e.g. codeine with acetaminophen); opioids were administered epidurally or intrathecally, as the epidural route is usually reserved for postoperative/labor pain, and while the intrathecal route is used in neuropathic pain (usually via an implantable pump) such therapy is typically classified as neuro‐modulation rather than analgesia; or if tramadol or tapentadol were used as the active drug, because, although both interact to some degree with opioid receptors, they are not regarded as pure opioid agonists. The efficacy of tramadol in relieving neuropathic pain has been reviewed elsewhere (<a href="./references#CD006146-bbs2-0087" title="DuehmkeRM , HollingsheadJ , CornblathDR . Tramadol for neuropathic pain. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD003726.pub3] ">Duehmke 2006</a>). </p> </section> <section id="CD006146-sec-0033"> <h4 class="title">Types of outcome measures</h4> <p>We included participant‐reported measure(s) of pain intensity or pain relief using validated methods. </p> <section id="CD006146-sec-0034"> <h5 class="title">Primary outcomes</h5> <p>In our updated review the primary outcomes we sought were the proportion of participants reporting at least 33% pain reduction from baseline or 50% or more pain reduction from baseline. The selection of these outcomes, as opposed to the primary outcomes in our original review (mean pain intensity difference or mean pain relief) was based on the observation that pain relief tends to be bimodal, rendering mean values less useful. A greater than or equal to 33% (or ≥ 30%) pain reduction from baseline was based upon analyses demonstrating that such a reduction was required for people with chronic pain to perceive a clinically meaningful change in pain intensity (<a href="./references#CD006146-bbs2-0091" title="FarrarJT , YoungJPJr , LaMoreauxL , WerthJL , PooleRM . Clinical importance of changes in chronic pain intensity measured on an 11‐point numerical pain rating scale. Pain2001;94:149‐58. ">Farrar 2001</a>). More recent evidence suggests that at least 50% pain relief is clinically significant, because high levels of pain relief are strongly associated with improved fatigue, sleep, depression, work ability and quality of life (<a href="./references#CD006146-bbs2-0103" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain2010;150:386‐9. '>Moore 2010a</a>). While such data are rarely reported in older studies, we anticipated that those studies found in our updated search would report them. </p> <p>Where studies did not report numbers of participants with at least 33% or 50% improvement, but reported numbers of participants reporting certain categories of global impression of change, e.g. "much improved", we translated these categories to equate to either at least 33% pain reduction from baseline or at least 50% pain reduction from baseline (<a href="./references#CD006146-bbs2-0089" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9:105‐21. ">Dworkin 2008</a>). </p> </section> <section id="CD006146-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p>We extracted data on the following secondary outcomes:</p> <p> <ol id="CD006146-list-0001"> <li> <p>Pain intensity or pain intensity difference or pain relief using a visual analog scale (VAS) or numerical rating scale (NRS). </p> </li> <li> <p>Outcomes based on pain questionnaires and quality of life (QoL) measurement instruments, including those recommended as core chronic pain outcome domains (<a href="./references#CD006146-bbs2-0089" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9:105‐21. ">Dworkin 2008</a>) (Multidimensional Pain Inventory and Brief Pain Inventory interference scales, Beck Depression Inventory and Profile of Mood States). </p> </li> <li> <p>Incidence of adverse events during treatment with opioid or control (intermediate‐term studies only). </p> </li> <li> <p>Participant dropouts due to adverse events (intermediate‐term studies only).</p> </li> <li> <p>Participant dropouts due to lack of efficacy (intermediate‐term studies only).</p> </li> </ol> </p> <p>We normalized pain intensity data assessed by means other than a 0 ‐ 100 VAS to such a scale. To do so we either multiplied the original scale employed by an appropriate factor (e.g. by ten if the original scale was a 0 ‐ 10 scale) or by assigning values on a 0 ‐ 100 scale that corresponded to choices on the original assessment scale. For example, if a participant was offered a five‐point scale, selection of the third point was scored as 50 on a 0 ‐ 100 scale (0 = no pain, 1 = 25, 2 = 50, 3 = 75, 4 = 100). </p> </section> </section> </section> <section id="CD006146-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <p>This search was run for the original review in June 2005 and subsequent searches were run on the 16th of August, 2010. Finally, further searches employing different search strategies were run on the 24th of October 2012. The new search strategies were developed because the older strategies produced an impractical number of references for only two years of literature. </p> <section id="CD006146-sec-0037"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases:</p> <p> <ul id="CD006146-list-0002"> <li> <p>CENTRAL, on <i>The Cochrane Library</i> (Issue 10 of 12, 2012) </p> </li> <li> <p>MEDLINE (1966 to Oct week 3, 2012)</p> </li> <li> <p>EMBASE (1980 to to 2012 week 42 )</p> </li> </ul> </p> <p>We combined search terms for RCTs with terms for opioids and terms for neuropathic pain. Our original search strategies can be found in <a href="./appendices#CD006146-sec-0095">Appendix 1</a>; <a href="./appendices#CD006146-sec-0096">Appendix 2</a>; and <a href="./appendices#CD006146-sec-0097">Appendix 3</a>. Our updated search strategies (2010 to 2012) can be found in <a href="./appendices#CD006146-sec-0098">Appendix 4</a>; <a href="./appendices#CD006146-sec-0099">Appendix 5</a>; and <a href="./appendices#CD006146-sec-0100">Appendix 6</a>. </p> <p>There was no language restriction.</p> </section> <section id="CD006146-sec-0038"> <h4 class="title">Searching other resources</h4> <p>We scanned the reference lists of reviews and retrieved articles. We did not consider abstracts or unpublished reports in this update, but intend to include them in future updates. </p> </section> </section> <section id="CD006146-sec-0039"> <h3 class="title" id="CD006146-sec-0039">Data collection and analysis</h3> <section id="CD006146-sec-0040"> <h4 class="title">Selection of studies</h4> <p>We determined eligibility by reading the abstract of each study identified by the search. We eliminated studies that clearly did not satisfy our inclusion criteria, and obtained full copies of the remaining studies. Two review authors read these studies independently and reached agreement by discussion. The studies were not anonymized in any way before assessment. </p> </section> <section id="CD006146-sec-0041"> <h4 class="title">Data extraction and management</h4> <p>Two review authors extracted and agreed on data, using a standard form, before entry into Review Manager 5 (RevMan). Data extracted included information on study design and duration, methods, interventions, pain outcomes, adverse events, diagnoses, participant inclusion and exclusion criteria, numbers enrolled and completing the study, and functional assessments. We resolved discrepancies in extracted data by discussion prior to their inclusion in the analyses. </p> <p>Analyses focused on differences in pain intensity, pain relief, and the incidence and severity of adverse events. When necessary and possible we normalized all data to a 0 ‐ 100 mm VAS. We made no attempt to convert surrogate outcomes (e.g. amount of rescue medication used) to a VAS, although we did equate certain global evaluations to either 33% or 50% pain reduction. For studies in which surrogate outcomes were the only results available, we describe them as such. We extracted the number of participants experiencing adverse events from trials in which they were asked about or observed for specific adverse effects such as constipation, also noting withdrawals if described. </p> </section> <section id="CD006146-sec-0042"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>In our original review, we graded included studies for methodological quality using the Oxford Quality Scale (<a href="./references#CD006146-bbs2-0096" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;17:1‐12. ">Jadad 1996</a>). In our updated review, we instead assessed 'Risk of bias' for both the original included studies and those included from the updated search (see <a href="#CD006146-sec-0042">Assessment of risk of bias in included studies</a>). Two review authors independently assessed the risk of bias of all included studies. The review authors made critical assessments for each of the following domains: sequence generation (randomization), allocation concealment, blinding, incomplete outcome data, and selective outcome reporting. The review author judgment for each domain was entered into a 'Risk of bias' table, with answers 'low risk', 'high risk' or 'unclear risk' (indicating either lack of information or uncertainty over the potential for bias). </p> </section> <section id="CD006146-sec-0043"> <h4 class="title">Measures of treatment effect</h4> <p>In contrast to our original review, we applied a random‐effects model to combine data, in part because of the heterogeneity apparent in many of the analyses. We are aware of the possible limitation of using a random‐effects model for meta‐analysis in case of non‐normal distribution of intervention effect data; however, using a fixed‐effect model for this purpose may be less appropriate since we cannot assume to know the direction of the effect. </p> <section id="CD006146-sec-0044"> <h5 class="title">Dichotomous data</h5> <p>Discrete events such as numbers of participants reporting 33% pain relief or better, or 50% pain relief or better, or the number of participants reporting adverse events were used to calculate the risk difference using Review Manager 5 software. When a statistically significant risk difference existed between interventions, we derived the number needed to treat for an additional beneficial outcome (NNTB) or for an additional harmful outcome (NNTH) (<a href="./references#CD006146-bbs2-0084" title="CookRJ , SackettDL . The number needed to treat: a clinically useful measure of treatment effect. BMJ1995;310:452‐4. ">Cook 1995</a>). Additionally, dichotomous outcomes are presented in terms of both raw numbers and percentages of participants in each study arm benefiting from therapy or suffering adverse events. </p> </section> <section id="CD006146-sec-0045"> <h5 class="title">Continuous data</h5> <p>We undertook meta‐analyses when comparable data were available from continuous outcomes. Comparisons between opioids and active control or placebo groups were made separately for pain relief, pain intensity post‐intervention, and intensity of a specific adverse event, using weighted mean differences (WMDs). </p> </section> </section> <section id="CD006146-sec-0046"> <h4 class="title">Unit of analysis issues</h4> <p>We split the control treatment arm between active treatment arms in a single study if the active treatment arms were not combined for analysis. </p> </section> <section id="CD006146-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>We did not contact authors for original data unless data were missing or unclear. If, despite attempts to contact study authors, participant data were missing, analyses were based on participant populations in which outcomes were reported. Discrepancies between the number of participants enrolled and the number of participants in whom outcomes were reported are noted in the <a href="./references#CD006146-sec-0111" title="">Characteristics of included studies</a> table. Where studies reported statistics based on intention‐to‐treat (ITT) or modified ITT populations, we performed available case analyses. The ITT population consisted of participants who were randomized, took the assigned study medication, and provided at least one post‐baseline assessment. </p> </section> <section id="CD006146-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>We evaluated heterogeneity between and within trials using both the Chi² test and the I² test. The Chi² test assesses whether observed differences in results are compatible with chance alone. A low P value (or a large Chi² statistic relative to its degrees of freedom) provides evidence of heterogeneity of treatment effects (variation in effect estimates beyond chance). The Chi² test has low power in estimating heterogeneity in the common situation where few trials are analyzed or where included trials have small sample sizes. Although a statistically significant result may indicate a problem with heterogeneity, a non‐significant result is not necessarily evidence of lack of heterogeneity. Methods developed for quantifying inconsistency across studies that move the focus away from testing whether heterogeneity is present to assessing its impact on the meta‐analysis include the I² statistic. I² = [(Q ‐df)/Q] x 100%, where Q is the Chi² statistic and df is its degrees of freedom (<a href="./references#CD006146-bbs2-0085" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions 5.1. Chichester: John Wiley &amp; Sons, 2011. ">Deeks 2011</a>; <a href="./references#CD006146-bbs2-0094" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in metaanalyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The I² statistic describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance). A value greater than 50% may be considered substantial heterogeneity (<a href="./references#CD006146-bbs2-0085" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions 5.1. Chichester: John Wiley &amp; Sons, 2011. ">Deeks 2011</a>). We also assessed heterogeneity by visually studying forest plots. </p> </section> <section id="CD006146-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>We made no attempt to assess reporting bias.</p> </section> <section id="CD006146-sec-0050"> <h4 class="title">Data synthesis</h4> <p>We used the random‐effects model by DerSimonian and Laird (<a href="./references#CD006146-bbs2-0085" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions 5.1. Chichester: John Wiley &amp; Sons, 2011. ">Deeks 2011</a>) for meta‐analysis, using Review Manager 5. </p> </section> <section id="CD006146-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where possible we performed subgroup analysis based on:</p> <p> <ul id="CD006146-list-0003"> <li> <p>peripheral versus central pain</p> </li> <li> <p>spontaneous versus evoked pain</p> </li> </ul> </p> </section> <section id="CD006146-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>For our updated review, we decided to perform sensitivity analyses by eliminating:</p> <p> <ul id="CD006146-list-0004"> <li> <p>cross‐over studies</p> </li> <li> <p>studies with fewer than 10 participants in an intervention arm or phase</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006146-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006146-sec-0053"></div> <section id="CD006146-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD006146-sec-0055"> <h4 class="title">Results of the search</h4> <p>Our 2005 literature search yielded 3823 citations (CENTRAL, 945; MEDLINE, 1531; EMBASE 1347), of which we selected 46 potentially relevant studies for retrieval. The literature search covering 2005 to 16 August 2010 yielded an additional 2409 citations (CENTRAL, 370; MEDLINE, 1025; EMBASE, 1014) of which we selected 19 studies for retrieval. Finally, the 2012 search yielded 2296 citations (CENTRAL, 157; MEDLINE, 1213; EMBASE, 926) of which we selected nine for retrieval (<a href="#CD006146-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD006146-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006146-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD006146-sec-0056"> <h4 class="title">Included studies</h4> <p>We divided the trials into two categories according to study duration. There is no definition per se of what constitutes a short‐term or an intermediate‐term trial. Short‐term trials, intuitively, were those that employed a single dose or intravenous infusion intervention. We labeled other trials as 'intermediate‐term' because we did not consider trial duration to be sufficiently long to make firm conclusions about chronic administration of opioids. In total, our updated review included 17 short‐term studies (three from the 2005 ‐ 2012 searches) and 14 intermediate‐term studies (five from the 2005 ‐ 2012 search). </p> <p>Eight of the 28 retrieved articles from the updated search (2010, 2012) met the inclusion criteria and provided data on an additional 510 participants with neuropathic pain who were treated with opioids. Three studies were short‐term trials: <a href="./references#CD006146-bbs2-0014" title="Juarez PichardoJS , Kassian RankAA , Hernandez PerezAL , Ramirez TapiaY . Comparison of the efficacy of oxycodone plus lidocaine versus tramadol plus lidocaine in continuous infusion in relieving acute neuropathic pain. Revista de la Sociedad Espanola del Dolor2009;16:307‐13. ">Juarez‐Pichardo 2009</a> (N = 27); <a href="./references#CD006146-bbs2-0026" title="SimpsonDM , MessinaJ , XieF , HaleM . Fentanyl buccal tablet for the relief of breakthrough pain in opioid‐tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2007;29:588‐601. ">Simpson 2007</a> (N = 79); and <a href="./references#CD006146-bbs2-0027" title="WallaceMS , MoulinD , ClarkAJ , WassermanR , NealeA , Morley‐ForsterP , et al. A Phase II, multicenter, randomized, double‐blind, placebo‐controlled crossover study of CJC‐1008 ‐ a long‐acting, parenteral opioid analgesic ‐ in the treatment of postherpetic neuralgia. Journal of Opioid Management2006;2:167‐73. ">Wallace 2006</a> (N = 32). The other five studies were intermediate‐term trials (<a href="./references#CD006146-bbs2-0006" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199‐201. ">Frank 2008</a>; <a href="./references#CD006146-bbs2-0009" title="HannaM , O'BrienC , WilsonMC . Prolonged‐release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. European Journal of Pain2008;12:804‐13. ">Hanna 2008</a>; <a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a>; <a href="./references#CD006146-bbs2-0032" title="WuCL , AgarwalS , TellaPK , KlickB , ClarkMR , HaythornthwaiteJA , et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo‐controlled, crossover trial. Anesthesiology2008;109:289‐96. ">Wu 2008</a>; <a href="./references#CD006146-bbs2-0033" title="ZinCS , NissenLM , O'CallaghanJP , DuffullSB , SmithMT , MooreBJ . A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. Journal of Pain2010;11:462‐71. ">Zin 2010</a>), in which opioids were administered orally over periods of between 35 and 84 days (median = 49 days). Numbers of participants per treatment group ranged from 29 to 169 (median = 50). </p> <p>Twenty‐three of the 46 articles from our 2005 search met the inclusion criteria and provided data on 727 participants with neuropathic pain who were treated with opioids. </p> <p>The first group consisted of 14 short‐term trials (treated as 16 comparisons) (<a href="./references#CD006146-bbs2-0001" title="ArnerS , MeyersonBA . Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain1988;33:11‐23. ">Arner 1988</a>; <a href="./references#CD006146-bbs2-0002" title="AttalN , GuirimandF , BrasseurL , GaudeV , ChauvinM , BouhassiraD . Effects of IV morphine in central pain: a randomized placebo‐controlled study. Neurology2002;58:554‐63. ">Attal 2002</a>; <a href="./references#CD006146-bbs2-0003" title="DellemijnPL , VannesteJA . Randomised double‐blind active‐placebo‐controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet1997;349:753‐8. ">Dellemijn 1997</a>; <a href="./references#CD006146-bbs2-0004" title="EidePK , JorumE , StubhaugA , BremnesJ , BreivikH . Relief of post‐herpetic neuralgia with the N‐methyl‐D‐aspartic acid receptor antagonist ketamine: a double‐blind, cross‐over comparison with morphine and placebo. Pain1994;58:347‐54. ">Eide 1994</a>; <a href="./references#CD006146-bbs2-0005" title="EidePK , StubhaugA , StenehjemAE . Central dysesthesia pain after traumatic spinal cord injury is dependent on N‐methyl‐D‐aspartate receptor activation. Neurosurgery1995;37:1080‐7. ">Eide 1995</a>; <a href="./references#CD006146-bbs2-0012" title="JadadAR , CarrollD , GlynnCJ , MooreRA , McQuayHJ . Morphine responsiveness of chronic pain: double‐blind randomised crossover study with patient‐controlled analgesia. Lancet1992;339:1367‐71. ">Jadad 1992</a>; <a href="./references#CD006146-bbs2-0013" title="JorumE , WarnckeT , StubhaugA . Cold allodynia and hyperalgesia in neuropathic pain: the effect of N‐methyl‐D‐aspartate (NMDA) receptor antagonist ketamine‐a double‐blind, cross‐over comparison with alfentanil and placebo. Pain2003;101:229‐35. ">Jorum 2003</a>; <a href="./references#CD006146-bbs2-0016" title="KupersRC , KoningsH , AdriaensenH , GybelsJM . Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain1991;47:5‐12. ">Kupers 1991 central</a>; <a href="./references#CD006146-bbs2-0017" title="KupersRC , KoningsH , AdriaensenH , GybelsJM . Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain1991;47:5‐12. ">Kupers 1991 peripheral</a>; <a href="./references#CD006146-bbs2-0018" title="LeungA , WallaceMS , RidgewayB , YakshT . Concentration‐effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain2001;91:177‐87. ">Leung 2001</a>; <a href="./references#CD006146-bbs2-0019" title="MaxMB , SchaferSC , CulnaneM , DubnerR , GracelyRH . Association of pain relief with drug side effects in postherpetic neuralgia: a single‐dose study of clonidine, codeine, ibuprofen, and placebo. Clinical Pharmacology and Therapeutics1988;43:363‐71. ">Max 1988</a>; <a href="./references#CD006146-bbs2-0020" title="MaxMB , Byas‐SmithMG , GracelyRH , BennettGJ . Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double‐blind comparison to alfentanil and placebo. Clinical Neuropharmacology1995;18:360‐8. ">Max 1995</a>; <a href="./references#CD006146-bbs2-0022" title="RabbenT , SkjelbredP , OyeI . Prolonged analgesic effect of ketamine, an N‐methyl‐D‐aspartate receptor inhibitor, in patients with chronic pain. Journal of Pharmacology and Experimental Therapeutics1999;289:1060‐6. ">Rabben 1999</a>; <a href="./references#CD006146-bbs2-0024" title="RowbothamMC , Reisner‐KellerLA , FieldsHL . Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology1991;41:1024‐8. ">Rowbotham 1991</a>; <a href="./references#CD006146-bbs2-0030" title="WuCL , TellaP , StaatsPS , VaslavR , KazimDA , WesselmannU , et al. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double‐blind, active placebo‐controlled, crossover trial. Anesthesiology2002;96:841‐8. ">Wu 2002 phantom limb</a>; <a href="./references#CD006146-bbs2-0031" title="WuCL , TellaP , StaatsPS , VaslavR , KazimDA , WesselmannU , et al. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double‐blind, active placebo‐controlled, crossover trial. Anesthesiology2002;96:841‐8. ">Wu 2002 stump</a>) in which opioids were administered mostly as brief intravenous infusions and outcomes were measured for less than 24 hours. The number of participants in each of these studies was small (median = 13; range, 7 to 53). We subanalyzed reported outcomes from two of the trials. In one study people with both peripheral and central pain were included and the results reported separately (<a href="./references#CD006146-bbs2-0016" title="KupersRC , KoningsH , AdriaensenH , GybelsJM . Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain1991;47:5‐12. ">Kupers 1991 central</a>; <a href="./references#CD006146-bbs2-0017" title="KupersRC , KoningsH , AdriaensenH , GybelsJM . Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain1991;47:5‐12. ">Kupers 1991 peripheral</a>). In another study changes in phantom limb pain and stump pain were reported separately (<a href="./references#CD006146-bbs2-0030" title="WuCL , TellaP , StaatsPS , VaslavR , KazimDA , WesselmannU , et al. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double‐blind, active placebo‐controlled, crossover trial. Anesthesiology2002;96:841‐8. ">Wu 2002 phantom limb</a>; <a href="./references#CD006146-bbs2-0031" title="WuCL , TellaP , StaatsPS , VaslavR , KazimDA , WesselmannU , et al. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double‐blind, active placebo‐controlled, crossover trial. Anesthesiology2002;96:841‐8. ">Wu 2002 stump</a>). </p> <p>The second group of studies consisted of nine intermediate‐term trials (<a href="./references#CD006146-bbs2-0007" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352:1324‐34. ">Gilron 2005</a>; <a href="./references#CD006146-bbs2-0008" title="GimbelJS , RichardsP , PortenoyRK . Controlled‐release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology2003;60:927‐34. JensenMP , FriedmanM , BonzoD , RichardsP . The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clinical Journal of Pain2006;22:97‐103. ">Gimbel 2003</a>; <a href="./references#CD006146-bbs2-0010" title="HarkeH , GretenkortP , LadleifHU , RahmanS , HarkeO . The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained‐release morphine in patients pretreated with spinal cord stimulation: a double‐blinded randomized study. Anesthesia and Analgesia2001;92:488‐95. ">Harke 2001</a>; <a href="./references#CD006146-bbs2-0011" title="HuseE , LarbigW , FlorH , BirbaumerN . The effect of opioids on phantom limb pain and cortical reorganization. Pain2001;90:47‐55. ">Huse 2001</a>; <a href="./references#CD006146-bbs2-0021" title="MorleyJS , BridsonJ , NashTP , MilesJB , WhiteS , MakinMK . Low‐dose methadone has an analgesic effect in neuropathic pain: a double‐blind randomized controlled crossover trial. Palliative Medicine2003;17:576‐87. ">Morley 2003</a>; <a href="./references#CD006146-bbs2-0023" title="RajaSN , HaythornthwaiteJA , PappagalloM , ClarkMR , TravisonTG , SabeenS , et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo‐controlled trial. Neurology2002;59:1015‐21. ">Raja 2002</a>; <a href="./references#CD006146-bbs2-0025" title="RowbothamMC , TwillingL , DaviesPS , ReisnerL , TaylorK , MohrD . Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine2003;348:1223‐32. ">Rowbotham 2003</a>; <a href="./references#CD006146-bbs2-0028" title="WatsonCP , BabulN . Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology1998;50:1837‐41. ">Watson 1998</a>; <a href="./references#CD006146-bbs2-0029" title="WatsonCP , MoulinD , Watt‐WatsonJ , GordonA , EisenhofferJ . Controlled‐release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain2003;105:71‐8. ">Watson 2003</a>) in which opioids were administered orally over longer periods of between eight and 70 days (median = 28 days), generally to larger numbers of participants (median = 57; range, 12 to 159). </p> </section> <section id="CD006146-sec-0057"> <h4 class="title">Excluded studies</h4> <p>Three controlled trials (<a href="./references#CD006146-bbs2-0037" title="BenedettiF , VighettiS , AmanzioM , CasadioC , OliaroA , BergamascoB , et al. Dose‐response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain1998;74:205‐11. ">Benedetti 1998</a>; <a href="./references#CD006146-bbs2-0049" title="KalmanS , OsterbergA , SorensenJ , BoivieJ , BertlerA . Morphine responsiveness in a group of well‐defined multiple sclerosis patients: a study with IV morphine. European Journal of Pain2002;6:69‐80. ">Kalman 2002</a>; <a href="./references#CD006146-bbs2-0053" title="MaierC , HildebrandtJ , KlingerR , Henrich‐EberlC , LindenaG , MONTAS Study Group. Morphine responsiveness, efficacy and tolerability in patients with chronic non‐tumor associated pain‐results of a double‐blind placebo‐controlled trial (MONTAS). Pain2002;97:223‐33. ">Maier 2002</a>) failed to meet one or more of the inclusion criteria in our original review. First, an RCT conducted over seven days (<a href="./references#CD006146-bbs2-0053" title="MaierC , HildebrandtJ , KlingerR , Henrich‐EberlC , LindenaG , MONTAS Study Group. Morphine responsiveness, efficacy and tolerability in patients with chronic non‐tumor associated pain‐results of a double‐blind placebo‐controlled trial (MONTAS). Pain2002;97:223‐33. ">Maier 2002</a>) compared morphine with placebo in a mixed group of participants with various neuropathic and nociceptive pain syndromes. The authors reported that "the number of responders was significantly higher in patients with neuropathic than with nociceptive pain". However, efficacy and adverse event data were not presented separately for the different types of pain. Second, a short‐term, placebo‐controlled trial (<a href="./references#CD006146-bbs2-0049" title="KalmanS , OsterbergA , SorensenJ , BoivieJ , BertlerA . Morphine responsiveness in a group of well‐defined multiple sclerosis patients: a study with IV morphine. European Journal of Pain2002;6:69‐80. ">Kalman 2002</a>) showed that only four of 14 participants who had multiple sclerosis and central neuropathic pain were categorized as 'responders' to intravenous morphine. The study was non‐randomized and single blinded. Third, in an RCT (<a href="./references#CD006146-bbs2-0037" title="BenedettiF , VighettiS , AmanzioM , CasadioC , OliaroA , BergamascoB , et al. Dose‐response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain1998;74:205‐11. ">Benedetti 1998</a>), five different doses of buprenorphine (0.033 to 0.166 mg) were administered randomly to 21 participants with post‐thoracotomy neuropathic pain one month after surgery, with reduction of pain by 50% in each person. However, buprenorphine is a partial mu receptor agonist, with different pharmacological properties to members of the full µ opioid agonist class. </p> <p>Twenty studies were excluded from the updated search (2005 ‐ 2012). Three trials included participants in whom pain could not be attributed entirely to neuropathic origin: in two of them participants with acute herpes zoster were enrolled (<a href="./references#CD006146-bbs2-0045" title="GuoW , XiaoZ , YangY . Effectiveness of transdermal fentanyl combined with clodine for pain control of acute herpes zoster. Journal of Dalian Medical University2007;29:255‐6. ">Guo 2007</a><b>;</b><a href="./references#CD006146-bbs2-0043" title="DworkinRH , BarbanoRL , TyringSK , BettsRF , McDermottMP , Pennella‐VaughanJ , et al. A randomized, placebo‐controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain2009;142:209‐17. ">Dworkin 2009</a>); and the third consisted of participants with low back pain (<a href="./references#CD006146-bbs2-0050" title="KalsoE , SimpsonKH , SlappendelR , DejonckheereJ , RicharzU . Predicting long‐term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine. BMC Medicine2007;5:39. ">Kalso 2007</a>). The potential cause of pain in these participants can be nociceptive, neuropathic or both, and the effect of opioid treatment on the two types of pain was not reported separately. Similarly, six other trials (<a href="./references#CD006146-bbs2-0036" title="AshburnMA , SlevinKA , MessinaJ , XieF . The efficacy and safety of fentanyl buccal tablet compared with immediate‐release oxycodone for the management of breakthrough pain in opioid‐tolerant patients with chronic pain. Anesthesia and Analgesia2011;112:693‐702. ">Ashburn 2011</a>; <a href="./references#CD006146-bbs2-0042" title="CrucianiRA , KatzN , PortenoyRK . Dose equivalence of immediate‐release hydromorphone and once‐daily osmotic‐controlled extended‐release hydromorphone: A randomized, double‐blind trial incorporating a measure of assay sensitivity. Journal of Pain2012;13:379‐89. ">Cruciani 2012</a>; <a href="./references#CD006146-bbs2-0058" title="NicholsonB , RossE , WeilA , SasakiJ , SacksG . Treatment of chronic moderate‐to‐severe non‐malignant pain with polymer‐coated extended‐release morphine sulfate capsules. Current Medical Research and Opinion2006;22:539‐50. ">Nicholson 2006a</a>; <a href="./references#CD006146-bbs2-0059" title="NicholsonB , RossE , SasakiJ , WeilA . Randomized trial comparing polymer‐coated extended‐release morphine sulfate to controlled‐release oxycodone HCl in moderate to severe nonmalignant pain. Current Medical Research and Opinion2006;22:1503‐14. ">Nicholson 2006b</a>; <a href="./references#CD006146-bbs2-0072" title="WebsterLR , BrewerR , WangC , SekoraD , JohnsonFK , MorrisD , et al. Long‐term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. Journal of Pain and Symptom Management2010;40:734‐46. ">Webster 2010</a>; <a href="./references#CD006146-bbs2-0074" title="WeilAJ , NicholsonB , SasakiJ . Factors affecting dosing regimens of morphine sulfate extended‐release (KADIAN) capsules. Journal of Opioid Management2009;5:39‐45. ">Weil 2009</a>) were excluded because enrolled participants had mixed pain syndromes (neuropathic or nociceptive) and results were not presented independently. Two trials included participants with neuropathic pain who were treated with opioids but were not RCTs (<a href="./references#CD006146-bbs2-0034" title="AritaH , HayashidaM , MizunoJ , OgawaS , HanaokaK . Pharmacological classification of intractable chronic pain (drug challenge tests). Japanese Journal of Anesthesiology2008;57:1330‐6. ">Arita 2008</a>; <a href="./references#CD006146-bbs2-0044" title="GattiA , SabatoAF , OcchioniR , Colini BaldeschiG , RealeC . Controlled‐release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. European Neurology2009;61:129‐37. ">Gatti 2009</a>). Two studies had no control group (<a href="./references#CD006146-bbs2-0057" title="MordarskiS , LysenkoL , GerberH , ZietekM , GredesT , DominiakM . The effect of treatment with fentanyl patches on pain relief and improvement in overall daily functioning in patients with postherpetic neuralgia. Journal of Physiology and Pharmacology2009;60:S8: 31‐5. ">Mordarski 2009</a>; <a href="./references#CD006146-bbs2-0076" title="YaoP , MengLX , MaJM , DingYY , WangZB , ZhaoGL , et al. Sustained‐release oxycodone tablets for moderate to severe painful diabetic peripheral neuropathy: a multicenter, open‐labeled, postmarketing clinical observation. Pain Medicine2012;13:107‐14. ">Yao 2012</a>). In one study the control group did not have neuropathic pain (<a href="./references#CD006146-bbs2-0060" title="NiestersM , HoitsmaE , SartonE , AartsL , DahanA . Offset analgesia in neuropathic pain patients and effect of treatment with morphine and ketamine. Anesthesiology2011;115:1063‐71. ">Niesters 2011</a>). Finally, six trials were published in an abstract form only (<a href="./references#CD006146-bbs2-0039" title="BuynakR , ShapiroD , OkamotoA , VanHoveI , EtropolskiM . Efficacy and safety of tapentadol ER for chronic low back pain: results of a randomized, double‐blind, placebo‐ and active‐controlled phase III study. Journal of Pain2009;10:s50. ">Buynak 2009</a>; <a href="./references#CD006146-bbs2-0047" title="HaleM , RauckR , LiS , KutchM . A randomized, double‐blind study of OROS® hydromorphone extended release compared to placebo in opioid‐tolerant patients with moderate‐to‐severe chronic low back pain. Journal of Pain2009;10:S50. ">Hale 2009</a>; <a href="./references#CD006146-bbs2-0061" title="OhC , BiondiDM , XiangJ , EtropolskiM . The efficacy and tolerability of tapentadol Immediate Release (IR) Versus Oxycodone IR for moderate to severe acute low back pain with radicular leg pain. Pain Medicine2012;13:330‐1. ">Oh 2012</a>; <a href="./references#CD006146-bbs2-0065" title="PodolskyG , AhdiehH , MaT . Randomized clinical trial of the safety and efficacy of oxymorphone extended release for degenerative disc disease in opioid‐naive patients. Journal of Pain2009;10:S48. ">Podolsky 2009</a>; <a href="./references#CD006146-bbs2-0071" title="VarrassiG , AshburnM , SlevinKA , NarayanaA , XieF . Fentanyl buccal tablet vs immediate‐release oxycodone for the management of breakthrough pain in opioid‐tolerant patients with chronic pain. European Journal of Pain2011;5:S87. ">Varrassi 2011</a>; <a href="./references#CD006146-bbs2-0073" title="WebsterL , NarayanaA , JankaL . Functioning/satisfaction with fentanyl buccal tablet compared to traditional short‐acting opioids for the management of breakthrough pain in opioid‐tolerant patients with chronic pain. Journal of Pain2011;12:P62. ">Webster 2011</a>). </p> </section> </section> <section id="CD006146-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>Our original review used the Oxford Quality Scale to assess the quality of each included study. In the updated review we replaced this scale with the 'Risk of bias' tool, applying it both to new studies and to those from the original review. A summary of 'Risk of bias' assessments can be found in <a href="#CD006146-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD006146-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006146-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006146-sec-0059"> <h4 class="title">Allocation</h4> <p>Fifteen of the 31 studies described methods for randomization adequately so that they could be assigned a low risk of bias for sequence generation. Ten of the 31 described methods of allocation concealment sufficiently that they could be assigned a low risk of bias. In both cases, the remaining studies did not provide enough information for us to draw any conclusion regarding risk of bias. Also in both cases, the majority of intermediate‐term studies had a low risk of bias, whereas a minority of short‐term studies described methods adequately. Among the intermediate‐term studies, low risk of bias was seen in similar numbers between parallel and cross‐over studies. </p> </section> <section id="CD006146-sec-0060"> <h4 class="title">Blinding</h4> <p>Only five of the 17 short‐term studies described methods of blinding sufficiently to be assigned a low risk of bias. Conversely, 10 of the 14 intermediate‐term studies were assigned a low risk of bias, with similar numbers between parallel and cross‐over studies. All other studies were assigned an unclear risk of bias due to inadequate information. </p> </section> <section id="CD006146-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>Given their nature, the majority of short‐term studies (13/17) had a low risk of attrition bias. Among the intermediate‐term studies only six of 14 were assigned a low risk of bias, with one study (<a href="./references#CD006146-bbs2-0025" title="RowbothamMC , TwillingL , DaviesPS , ReisnerL , TaylorK , MohrD . Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine2003;348:1223‐32. ">Rowbotham 2003</a>) assigned a high risk. In this study 12/43 participants in the high‐dose levorphanol arm and 3/38 in the low‐dose arm withdrew from the study due to adverse events. All other studies were assigned an unclear risk: <a href="./references#CD006146-bbs2-0006" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199‐201. ">Frank 2008</a> reported both available case analysis and per protocol analysis, but a greater number of subjects withdrew due to side effects while assigned an opioid; in <a href="./references#CD006146-bbs2-0007" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352:1324‐34. ">Gilron 2005</a> withdrawals (16/57) were evenly distributed among groups, but reasons for withdrawal not fully described; <a href="./references#CD006146-bbs2-0008" title="GimbelJS , RichardsP , PortenoyRK . Controlled‐release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology2003;60:927‐34. JensenMP , FriedmanM , BonzoD , RichardsP . The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clinical Journal of Pain2006;22:97‐103. ">Gimbel 2003</a> and <a href="./references#CD006146-bbs2-0009" title="HannaM , O'BrienC , WilsonMC . Prolonged‐release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. European Journal of Pain2008;12:804‐13. ">Hanna 2008</a> imputed data using last observation carried forward (LOCF); <a href="./references#CD006146-bbs2-0011" title="HuseE , LarbigW , FlorH , BirbaumerN . The effect of opioids on phantom limb pain and cortical reorganization. Pain2001;90:47‐55. ">Huse 2001</a> made no mention of how missing data were imputed; in <a href="./references#CD006146-bbs2-0021" title="MorleyJS , BridsonJ , NashTP , MilesJB , WhiteS , MakinMK . Low‐dose methadone has an analgesic effect in neuropathic pain: a double‐blind randomized controlled crossover trial. Palliative Medicine2003;17:576‐87. ">Morley 2003</a> only study completers were analyzed, six participants withdrew from the high‐dose phase due to severe nausea ‐ three while taking placebo, three while taking methadone ‐ while number of withdrawals were small, group sizes were also small. Finally, <a href="./references#CD006146-bbs2-0023" title="RajaSN , HaythornthwaiteJA , PappagalloM , ClarkMR , TravisonTG , SabeenS , et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo‐controlled trial. Neurology2002;59:1015‐21. ">Raja 2002</a> employed an ITT analysis. For participants who did not complete a treatment period, the last three available pain ratings were used. However, the number of participants who did not complete the opioid phase was not reported. </p> </section> <section id="CD006146-sec-0062"> <h4 class="title">Selective reporting</h4> <p>The vast majority of both short‐ and intermediate‐term studies reported data on all of the outcomes described in their Methods sections. While study protocols were not available for any of the reported trials, and it is therefore possible that certain outcomes were measured but not reported, the widespread reporting of pain intensity and pain relief values leads us to believe that reporting was complete for most studies. </p> </section> <section id="CD006146-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>Treatment group size was an issue, particularly in short‐term studies. Numbers enrolled in each study ranged from 7 to 79 in short‐term trials, with five studies enrolling fewer than 10 participants (<a href="./references#CD006146-bbs2-0001" title="ArnerS , MeyersonBA . Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain1988;33:11‐23. ">Arner 1988</a>; <a href="./references#CD006146-bbs2-0004" title="EidePK , JorumE , StubhaugA , BremnesJ , BreivikH . Relief of post‐herpetic neuralgia with the N‐methyl‐D‐aspartic acid receptor antagonist ketamine: a double‐blind, cross‐over comparison with morphine and placebo. Pain1994;58:347‐54. ">Eide 1994</a>; <a href="./references#CD006146-bbs2-0005" title="EidePK , StubhaugA , StenehjemAE . Central dysesthesia pain after traumatic spinal cord injury is dependent on N‐methyl‐D‐aspartate receptor activation. Neurosurgery1995;37:1080‐7. ">Eide 1995</a>; <a href="./references#CD006146-bbs2-0012" title="JadadAR , CarrollD , GlynnCJ , MooreRA , McQuayHJ . Morphine responsiveness of chronic pain: double‐blind randomised crossover study with patient‐controlled analgesia. Lancet1992;339:1367‐71. ">Jadad 1992</a>; <a href="./references#CD006146-bbs2-0020" title="MaxMB , Byas‐SmithMG , GracelyRH , BennettGJ . Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double‐blind comparison to alfentanil and placebo. Clinical Neuropharmacology1995;18:360‐8. ">Max 1995</a>) and a further five enrolling fewer than 20 participants (<a href="./references#CD006146-bbs2-0002" title="AttalN , GuirimandF , BrasseurL , GaudeV , ChauvinM , BouhassiraD . Effects of IV morphine in central pain: a randomized placebo‐controlled study. Neurology2002;58:554‐63. ">Attal 2002</a>; <a href="./references#CD006146-bbs2-0013" title="JorumE , WarnckeT , StubhaugA . Cold allodynia and hyperalgesia in neuropathic pain: the effect of N‐methyl‐D‐aspartate (NMDA) receptor antagonist ketamine‐a double‐blind, cross‐over comparison with alfentanil and placebo. Pain2003;101:229‐35. ">Jorum 2003</a>; <a href="./references#CD006146-bbs2-0016" title="KupersRC , KoningsH , AdriaensenH , GybelsJM . Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain1991;47:5‐12. ">Kupers 1991 central</a>; <a href="./references#CD006146-bbs2-0018" title="LeungA , WallaceMS , RidgewayB , YakshT . Concentration‐effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain2001;91:177‐87. ">Leung 2001</a>; <a href="./references#CD006146-bbs2-0024" title="RowbothamMC , Reisner‐KellerLA , FieldsHL . Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology1991;41:1024‐8. ">Rowbotham 1991</a>). In intermediate‐term studies, enrolled arms (parallel studies) or phases (cross‐over studies) ranged in size from 12 to 169 participants. Amongst the intermediate‐term studies, the mean number of participants enrolled in each arm in parallel studies was 60, whereas the mean total enrolment size in cross‐over studies was 52. Studies with small group sizes may overestimate efficacy (<a href="./references#CD006146-bbs2-0102" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;7:209‐16. ">Moore 1998</a>; <a href="./references#CD006146-bbs2-0109" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ2010;341:c3515. ">Nuesch 2010</a>). </p> <p>Evidence from trials in people with arthritis shows that studies lasting less than eight weeks overestimate the effect of treatment (<a href="./references#CD006146-bbs2-0104" title="MooreRA , MooreOA , DerryS , PelosoPM , GammaitoniAR , WangH . Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases2010;69:374‐9. ">Moore 2010b</a>); the same may be true in studies of neuropathic pain, given that typically both are chronic conditions. Of the 14 intermediate‐term studies, nine had treatment phases that lasted less than eight weeks (<a href="./references#CD006146-bbs2-0006" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199‐201. ">Frank 2008</a>; <a href="./references#CD006146-bbs2-0007" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352:1324‐34. ">Gilron 2005</a>; <a href="./references#CD006146-bbs2-0008" title="GimbelJS , RichardsP , PortenoyRK . Controlled‐release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology2003;60:927‐34. JensenMP , FriedmanM , BonzoD , RichardsP . The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clinical Journal of Pain2006;22:97‐103. ">Gimbel 2003</a>; <a href="./references#CD006146-bbs2-0010" title="HarkeH , GretenkortP , LadleifHU , RahmanS , HarkeO . The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained‐release morphine in patients pretreated with spinal cord stimulation: a double‐blinded randomized study. Anesthesia and Analgesia2001;92:488‐95. ">Harke 2001</a>; <a href="./references#CD006146-bbs2-0011" title="HuseE , LarbigW , FlorH , BirbaumerN . The effect of opioids on phantom limb pain and cortical reorganization. Pain2001;90:47‐55. ">Huse 2001</a>; <a href="./references#CD006146-bbs2-0021" title="MorleyJS , BridsonJ , NashTP , MilesJB , WhiteS , MakinMK . Low‐dose methadone has an analgesic effect in neuropathic pain: a double‐blind randomized controlled crossover trial. Palliative Medicine2003;17:576‐87. ">Morley 2003</a>; <a href="./references#CD006146-bbs2-0028" title="WatsonCP , BabulN . Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology1998;50:1837‐41. ">Watson 1998</a>; <a href="./references#CD006146-bbs2-0029" title="WatsonCP , MoulinD , Watt‐WatsonJ , GordonA , EisenhofferJ . Controlled‐release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain2003;105:71‐8. ">Watson 2003</a>; <a href="./references#CD006146-bbs2-0033" title="ZinCS , NissenLM , O'CallaghanJP , DuffullSB , SmithMT , MooreBJ . A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. Journal of Pain2010;11:462‐71. ">Zin 2010</a>), and only one study was conducted over 12 weeks (<a href="./references#CD006146-bbs2-0009" title="HannaM , O'BrienC , WilsonMC . Prolonged‐release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. European Journal of Pain2008;12:804‐13. ">Hanna 2008</a>). The five parallel studies had a mean duration of 6.4 weeks, whereas the nine cross‐over studies had a mean duration of 5.7 weeks. </p> </section> </section> <section id="CD006146-sec-0064"> <h3 class="title" id="CD006146-sec-0064">Effects of interventions</h3> <section id="CD006146-sec-0065"> <h4 class="title">Short‐term studies</h4> <p>Our updated search added two cross‐over and one parallel study, which provided additional efficacy data for opioids in 125 participants with neuropathic pain. None of the three studies presented data in a format that we were able to add to our short‐term study meta‐analyses. In total, 17 RCTs provided efficacy data for acute exposure to opioids in 392 participants with neuropathic pain. In the three new studies, drugs were administered buccally (<a href="./references#CD006146-bbs2-0026" title="SimpsonDM , MessinaJ , XieF , HaleM . Fentanyl buccal tablet for the relief of breakthrough pain in opioid‐tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2007;29:588‐601. ">Simpson 2007</a>) and intravenously (<a href="./references#CD006146-bbs2-0014" title="Juarez PichardoJS , Kassian RankAA , Hernandez PerezAL , Ramirez TapiaY . Comparison of the efficacy of oxycodone plus lidocaine versus tramadol plus lidocaine in continuous infusion in relieving acute neuropathic pain. Revista de la Sociedad Espanola del Dolor2009;16:307‐13. ">Juarez‐Pichardo 2009</a>; <a href="./references#CD006146-bbs2-0027" title="WallaceMS , MoulinD , ClarkAJ , WassermanR , NealeA , Morley‐ForsterP , et al. A Phase II, multicenter, randomized, double‐blind, placebo‐controlled crossover study of CJC‐1008 ‐ a long‐acting, parenteral opioid analgesic ‐ in the treatment of postherpetic neuralgia. Journal of Opioid Management2006;2:167‐73. ">Wallace 2006</a>). In total, drugs were administered intravenously in 14 trials, orally in one (<a href="./references#CD006146-bbs2-0019" title="MaxMB , SchaferSC , CulnaneM , DubnerR , GracelyRH . Association of pain relief with drug side effects in postherpetic neuralgia: a single‐dose study of clonidine, codeine, ibuprofen, and placebo. Clinical Pharmacology and Therapeutics1988;43:363‐71. ">Max 1988</a>), intramuscularly in one (<a href="./references#CD006146-bbs2-0022" title="RabbenT , SkjelbredP , OyeI . Prolonged analgesic effect of ketamine, an N‐methyl‐D‐aspartate receptor inhibitor, in patients with chronic pain. Journal of Pharmacology and Experimental Therapeutics1999;289:1060‐6. ">Rabben 1999</a>) and buccally in one (<a href="./references#CD006146-bbs2-0026" title="SimpsonDM , MessinaJ , XieF , HaleM . Fentanyl buccal tablet for the relief of breakthrough pain in opioid‐tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2007;29:588‐601. ">Simpson 2007</a>). The duration of treatment varied from seconds (i.e. a single intramuscular injection) to eight hours, but was less than one hour in 10 trials. The tested drug was morphine in seven trials, alfentanil in four, fentanyl in two, and oxycodone, meperidine, codeine, or the investigational drug CJC‐1008 (a chemical modification of the opioid peptide dynorphin A) in one trial each. Placebo was used as a control in 14 trials. The diagnosis was specified in all trials: four trials included people with postherpetic neuralgia (PHN) only (<a href="./references#CD006146-bbs2-0004" title="EidePK , JorumE , StubhaugA , BremnesJ , BreivikH . Relief of post‐herpetic neuralgia with the N‐methyl‐D‐aspartic acid receptor antagonist ketamine: a double‐blind, cross‐over comparison with morphine and placebo. Pain1994;58:347‐54. ">Eide 1994</a>; <a href="./references#CD006146-bbs2-0019" title="MaxMB , SchaferSC , CulnaneM , DubnerR , GracelyRH . Association of pain relief with drug side effects in postherpetic neuralgia: a single‐dose study of clonidine, codeine, ibuprofen, and placebo. Clinical Pharmacology and Therapeutics1988;43:363‐71. ">Max 1988</a>; <a href="./references#CD006146-bbs2-0024" title="RowbothamMC , Reisner‐KellerLA , FieldsHL . Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology1991;41:1024‐8. ">Rowbotham 1991</a>; <a href="./references#CD006146-bbs2-0027" title="WallaceMS , MoulinD , ClarkAJ , WassermanR , NealeA , Morley‐ForsterP , et al. A Phase II, multicenter, randomized, double‐blind, placebo‐controlled crossover study of CJC‐1008 ‐ a long‐acting, parenteral opioid analgesic ‐ in the treatment of postherpetic neuralgia. Journal of Opioid Management2006;2:167‐73. ">Wallace 2006</a>); two involved people with post‐traumatic neuralgia (<a href="./references#CD006146-bbs2-0013" title="JorumE , WarnckeT , StubhaugA . Cold allodynia and hyperalgesia in neuropathic pain: the effect of N‐methyl‐D‐aspartate (NMDA) receptor antagonist ketamine‐a double‐blind, cross‐over comparison with alfentanil and placebo. Pain2003;101:229‐35. ">Jorum 2003</a>; <a href="./references#CD006146-bbs2-0020" title="MaxMB , Byas‐SmithMG , GracelyRH , BennettGJ . Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double‐blind comparison to alfentanil and placebo. Clinical Neuropharmacology1995;18:360‐8. ">Max 1995</a>); in seven, participants with mixed neuropathies were studied (<a href="./references#CD006146-bbs2-0001" title="ArnerS , MeyersonBA . Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain1988;33:11‐23. ">Arner 1988</a>; <a href="./references#CD006146-bbs2-0003" title="DellemijnPL , VannesteJA . Randomised double‐blind active‐placebo‐controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet1997;349:753‐8. ">Dellemijn 1997</a>; <a href="./references#CD006146-bbs2-0012" title="JadadAR , CarrollD , GlynnCJ , MooreRA , McQuayHJ . Morphine responsiveness of chronic pain: double‐blind randomised crossover study with patient‐controlled analgesia. Lancet1992;339:1367‐71. ">Jadad 1992</a>; <a href="./references#CD006146-bbs2-0014" title="Juarez PichardoJS , Kassian RankAA , Hernandez PerezAL , Ramirez TapiaY . Comparison of the efficacy of oxycodone plus lidocaine versus tramadol plus lidocaine in continuous infusion in relieving acute neuropathic pain. Revista de la Sociedad Espanola del Dolor2009;16:307‐13. ">Juarez‐Pichardo 2009</a>; <a href="./references#CD006146-bbs2-0016" title="KupersRC , KoningsH , AdriaensenH , GybelsJM . Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain1991;47:5‐12. ">Kupers 1991 central</a>; <a href="./references#CD006146-bbs2-0017" title="KupersRC , KoningsH , AdriaensenH , GybelsJM . Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain1991;47:5‐12. ">Kupers 1991 peripheral</a>; <a href="./references#CD006146-bbs2-0018" title="LeungA , WallaceMS , RidgewayB , YakshT . Concentration‐effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain2001;91:177‐87. ">Leung 2001</a>; <a href="./references#CD006146-bbs2-0026" title="SimpsonDM , MessinaJ , XieF , HaleM . Fentanyl buccal tablet for the relief of breakthrough pain in opioid‐tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2007;29:588‐601. ">Simpson 2007</a>); two included people with central pain (<a href="./references#CD006146-bbs2-0002" title="AttalN , GuirimandF , BrasseurL , GaudeV , ChauvinM , BouhassiraD . Effects of IV morphine in central pain: a randomized placebo‐controlled study. Neurology2002;58:554‐63. ">Attal 2002</a>; <a href="./references#CD006146-bbs2-0005" title="EidePK , StubhaugA , StenehjemAE . Central dysesthesia pain after traumatic spinal cord injury is dependent on N‐methyl‐D‐aspartate receptor activation. Neurosurgery1995;37:1080‐7. ">Eide 1995</a>); one involved people with secondary (e.g. post‐traumatic) trigeminal neuropathy (<a href="./references#CD006146-bbs2-0022" title="RabbenT , SkjelbredP , OyeI . Prolonged analgesic effect of ketamine, an N‐methyl‐D‐aspartate receptor inhibitor, in patients with chronic pain. Journal of Pharmacology and Experimental Therapeutics1999;289:1060‐6. ">Rabben 1999</a>); and one enrolled participants with postamputation stump and phantom pain (<a href="./references#CD006146-bbs2-0030" title="WuCL , TellaP , StaatsPS , VaslavR , KazimDA , WesselmannU , et al. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double‐blind, active placebo‐controlled, crossover trial. Anesthesiology2002;96:841‐8. ">Wu 2002 phantom limb</a>; <a href="./references#CD006146-bbs2-0031" title="WuCL , TellaP , StaatsPS , VaslavR , KazimDA , WesselmannU , et al. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double‐blind, active placebo‐controlled, crossover trial. Anesthesiology2002;96:841‐8. ">Wu 2002 stump</a>). Considerable variation between studies in duration of treatment, and method of pain assessment allowed only limited quantitative synthesis of data. </p> <section id="CD006146-sec-0066"> <h5 class="title">Outcomes assessed</h5> <p>A change in spontaneous pain intensity was the primary outcome measure in 16 trials. Authors reported mixed results with respect to the analgesic efficacy of opioids for neuropathic pain in general and for specific conditions (i.e. PHN, post‐traumatic neuralgia, and central pain). Eight trials showed greater efficacy of the tested opioid versus placebo (<a href="./references#CD006146-bbs2-0003" title="DellemijnPL , VannesteJA . Randomised double‐blind active‐placebo‐controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet1997;349:753‐8. ">Dellemijn 1997</a>; <a href="./references#CD006146-bbs2-0005" title="EidePK , StubhaugA , StenehjemAE . Central dysesthesia pain after traumatic spinal cord injury is dependent on N‐methyl‐D‐aspartate receptor activation. Neurosurgery1995;37:1080‐7. ">Eide 1995</a>; <a href="./references#CD006146-bbs2-0013" title="JorumE , WarnckeT , StubhaugA . Cold allodynia and hyperalgesia in neuropathic pain: the effect of N‐methyl‐D‐aspartate (NMDA) receptor antagonist ketamine‐a double‐blind, cross‐over comparison with alfentanil and placebo. Pain2003;101:229‐35. ">Jorum 2003</a>; <a href="./references#CD006146-bbs2-0018" title="LeungA , WallaceMS , RidgewayB , YakshT . Concentration‐effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain2001;91:177‐87. ">Leung 2001</a>; <a href="./references#CD006146-bbs2-0024" title="RowbothamMC , Reisner‐KellerLA , FieldsHL . Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology1991;41:1024‐8. ">Rowbotham 1991</a>; <a href="./references#CD006146-bbs2-0027" title="WallaceMS , MoulinD , ClarkAJ , WassermanR , NealeA , Morley‐ForsterP , et al. A Phase II, multicenter, randomized, double‐blind, placebo‐controlled crossover study of CJC‐1008 ‐ a long‐acting, parenteral opioid analgesic ‐ in the treatment of postherpetic neuralgia. Journal of Opioid Management2006;2:167‐73. ">Wallace 2006</a>; <a href="./references#CD006146-bbs2-0030" title="WuCL , TellaP , StaatsPS , VaslavR , KazimDA , WesselmannU , et al. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double‐blind, active placebo‐controlled, crossover trial. Anesthesiology2002;96:841‐8. ">Wu 2002 phantom limb</a>; <a href="./references#CD006146-bbs2-0031" title="WuCL , TellaP , StaatsPS , VaslavR , KazimDA , WesselmannU , et al. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double‐blind, active placebo‐controlled, crossover trial. Anesthesiology2002;96:841‐8. ">Wu 2002 stump</a>) or another active intervention (tramadol, <a href="./references#CD006146-bbs2-0014" title="Juarez PichardoJS , Kassian RankAA , Hernandez PerezAL , Ramirez TapiaY . Comparison of the efficacy of oxycodone plus lidocaine versus tramadol plus lidocaine in continuous infusion in relieving acute neuropathic pain. Revista de la Sociedad Espanola del Dolor2009;16:307‐13. ">Juarez‐Pichardo 2009</a>). In contrast, in five trials, researchers observed equivalent efficacy for opioids and placebo (<a href="./references#CD006146-bbs2-0001" title="ArnerS , MeyersonBA . Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain1988;33:11‐23. ">Arner 1988</a>; <a href="./references#CD006146-bbs2-0002" title="AttalN , GuirimandF , BrasseurL , GaudeV , ChauvinM , BouhassiraD . Effects of IV morphine in central pain: a randomized placebo‐controlled study. Neurology2002;58:554‐63. ">Attal 2002</a>; <a href="./references#CD006146-bbs2-0004" title="EidePK , JorumE , StubhaugA , BremnesJ , BreivikH . Relief of post‐herpetic neuralgia with the N‐methyl‐D‐aspartic acid receptor antagonist ketamine: a double‐blind, cross‐over comparison with morphine and placebo. Pain1994;58:347‐54. ">Eide 1994</a>; <a href="./references#CD006146-bbs2-0019" title="MaxMB , SchaferSC , CulnaneM , DubnerR , GracelyRH . Association of pain relief with drug side effects in postherpetic neuralgia: a single‐dose study of clonidine, codeine, ibuprofen, and placebo. Clinical Pharmacology and Therapeutics1988;43:363‐71. ">Max 1988</a>; <a href="./references#CD006146-bbs2-0020" title="MaxMB , Byas‐SmithMG , GracelyRH , BennettGJ . Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double‐blind comparison to alfentanil and placebo. Clinical Neuropharmacology1995;18:360‐8. ">Max 1995</a>). Two trials demonstrated partial efficacy, meaning that some participants responded to the opioid treatment while others did not (<a href="./references#CD006146-bbs2-0012" title="JadadAR , CarrollD , GlynnCJ , MooreRA , McQuayHJ . Morphine responsiveness of chronic pain: double‐blind randomised crossover study with patient‐controlled analgesia. Lancet1992;339:1367‐71. ">Jadad 1992</a>; <a href="./references#CD006146-bbs2-0022" title="RabbenT , SkjelbredP , OyeI . Prolonged analgesic effect of ketamine, an N‐methyl‐D‐aspartate receptor inhibitor, in patients with chronic pain. Journal of Pharmacology and Experimental Therapeutics1999;289:1060‐6. ">Rabben 1999</a>). Another trial showed a reduction in the affective but not in the sensory component of pain (<a href="./references#CD006146-bbs2-0016" title="KupersRC , KoningsH , AdriaensenH , GybelsJM . Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain1991;47:5‐12. ">Kupers 1991 central</a>; <a href="./references#CD006146-bbs2-0017" title="KupersRC , KoningsH , AdriaensenH , GybelsJM . Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain1991;47:5‐12. ">Kupers 1991 peripheral</a>). </p> <p>One study, from our updated search, assessed breakthrough pain (<a href="./references#CD006146-bbs2-0026" title="SimpsonDM , MessinaJ , XieF , HaleM . Fentanyl buccal tablet for the relief of breakthrough pain in opioid‐tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double‐blind, placebo‐controlled study. Clinical Therapeutics2007;29:588‐601. ">Simpson 2007</a>). Fentanyl tablets or placebo were administered buccally to treat nine consecutive episodes of breakthrough pain in each of 79 participants with mixed neuropathies. Drug efficacy was measured for up to 120 minutes for each episode. This study also differed from the other short‐term studies in that participants had up to 21 days to complete the nine separate assessments. Because of the unique study design, we were not able to combine data from this study with data from any of the other short‐term studies. The study demonstrated statistically significant superiority of fentanyl buccal tablets over placebo for several outcomes, including summed pain intensity over 60 minutes, SPID60 (mean (standard error), 9.63 (0.75) versus 5.73 (0.72), respectively; P &lt; 0.001) and proportion of breakthrough episodes with a at least 33% and at least 50% improvement in pain intensity from baseline compared with placebo from 10 minutes (9% versus 3%; P = 0.008) through two hours (66% versus 37%; P &lt; 0.001). </p> </section> <section id="CD006146-sec-0067"> <h5 class="title">Meta‐analysis</h5> <p>We combined data for meta‐analysis from four studies enrolling a total of 90 participants (<a href="./references#CD006146-bbs2-0002" title="AttalN , GuirimandF , BrasseurL , GaudeV , ChauvinM , BouhassiraD . Effects of IV morphine in central pain: a randomized placebo‐controlled study. Neurology2002;58:554‐63. ">Attal 2002</a>; <a href="./references#CD006146-bbs2-0016" title="KupersRC , KoningsH , AdriaensenH , GybelsJM . Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain1991;47:5‐12. ">Kupers 1991 central</a>; <a href="./references#CD006146-bbs2-0017" title="KupersRC , KoningsH , AdriaensenH , GybelsJM . Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain1991;47:5‐12. ">Kupers 1991 peripheral</a>; <a href="./references#CD006146-bbs2-0024" title="RowbothamMC , Reisner‐KellerLA , FieldsHL . Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology1991;41:1024‐8. ">Rowbotham 1991</a>; <a href="./references#CD006146-bbs2-0030" title="WuCL , TellaP , StaatsPS , VaslavR , KazimDA , WesselmannU , et al. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double‐blind, active placebo‐controlled, crossover trial. Anesthesiology2002;96:841‐8. ">Wu 2002 phantom limb</a>; <a href="./references#CD006146-bbs2-0031" title="WuCL , TellaP , StaatsPS , VaslavR , KazimDA , WesselmannU , et al. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double‐blind, active placebo‐controlled, crossover trial. Anesthesiology2002;96:841‐8. ">Wu 2002 stump</a>) (<a href="./references#CD006146-fig-0003" title="">Analysis 1.1</a>). The result of the Chi² test for heterogeneity was 0.55 (P = 0.99), and the I² was 0%, indicating homogeneity between and within studies. The overall mean difference in the last measured pain intensity for active treatment versus placebo was ‐16 (on a 0 ‐ 100 visual analog scale (VAS)) (95% CI ‐23 to ‐9; P &lt; 0.00001). We were able to conduct a subanalysis based on origin of neuropathic pain. Data from two trials including a total of 21 participants with central pain and from four trials involving 69 participants with peripheral neuropathic pain were subanalyzed (<a href="./references#CD006146-fig-0003" title="">Analysis 1.1</a>). For peripheral pain, the final pain intensity following opioid administration was 15 points lower than that after placebo (95% CI ‐23 to ‐7; P = 0.0002), whereas, for central pain, the difference was 18 points (95% CI ‐30 to ‐5; P = 0.006). </p> <p>When short‐term studies were categorized according to etiology, e.g. post‐traumatic neuralgia (<a href="./references#CD006146-bbs2-0013" title="JorumE , WarnckeT , StubhaugA . Cold allodynia and hyperalgesia in neuropathic pain: the effect of N‐methyl‐D‐aspartate (NMDA) receptor antagonist ketamine‐a double‐blind, cross‐over comparison with alfentanil and placebo. Pain2003;101:229‐35. ">Jorum 2003</a>; <a href="./references#CD006146-bbs2-0020" title="MaxMB , Byas‐SmithMG , GracelyRH , BennettGJ . Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double‐blind comparison to alfentanil and placebo. Clinical Neuropharmacology1995;18:360‐8. ">Max 1995</a>), PHN (<a href="./references#CD006146-bbs2-0004" title="EidePK , JorumE , StubhaugA , BremnesJ , BreivikH . Relief of post‐herpetic neuralgia with the N‐methyl‐D‐aspartic acid receptor antagonist ketamine: a double‐blind, cross‐over comparison with morphine and placebo. Pain1994;58:347‐54. ">Eide 1994</a>; <a href="./references#CD006146-bbs2-0019" title="MaxMB , SchaferSC , CulnaneM , DubnerR , GracelyRH . Association of pain relief with drug side effects in postherpetic neuralgia: a single‐dose study of clonidine, codeine, ibuprofen, and placebo. Clinical Pharmacology and Therapeutics1988;43:363‐71. ">Max 1988</a>; <a href="./references#CD006146-bbs2-0024" title="RowbothamMC , Reisner‐KellerLA , FieldsHL . Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology1991;41:1024‐8. ">Rowbotham 1991</a>), the results were equivocal. One within‐study comparison (<a href="./references#CD006146-bbs2-0012" title="JadadAR , CarrollD , GlynnCJ , MooreRA , McQuayHJ . Morphine responsiveness of chronic pain: double‐blind randomised crossover study with patient‐controlled analgesia. Lancet1992;339:1367‐71. ">Jadad 1992</a>) and two other between‐study comparisons (<a href="./references#CD006146-bbs2-0013" title="JorumE , WarnckeT , StubhaugA . Cold allodynia and hyperalgesia in neuropathic pain: the effect of N‐methyl‐D‐aspartate (NMDA) receptor antagonist ketamine‐a double‐blind, cross‐over comparison with alfentanil and placebo. Pain2003;101:229‐35. ">Jorum 2003</a> versus <a href="./references#CD006146-bbs2-0020" title="MaxMB , Byas‐SmithMG , GracelyRH , BennettGJ . Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double‐blind comparison to alfentanil and placebo. Clinical Neuropharmacology1995;18:360‐8. ">Max 1995</a> and <a href="./references#CD006146-bbs2-0004" title="EidePK , JorumE , StubhaugA , BremnesJ , BreivikH . Relief of post‐herpetic neuralgia with the N‐methyl‐D‐aspartic acid receptor antagonist ketamine: a double‐blind, cross‐over comparison with morphine and placebo. Pain1994;58:347‐54. ">Eide 1994</a> versus <a href="./references#CD006146-bbs2-0024" title="RowbothamMC , Reisner‐KellerLA , FieldsHL . Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology1991;41:1024‐8. ">Rowbotham 1991</a>) of 'high' versus 'low' opioid doses did not show an association between the opioid dose administered and analgesic efficacy. Two trials reported results in terms of percentage reduction in pain (<a href="./references#CD006146-bbs2-0018" title="LeungA , WallaceMS , RidgewayB , YakshT . Concentration‐effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain2001;91:177‐87. ">Leung 2001</a>; <a href="./references#CD006146-bbs2-0020" title="MaxMB , Byas‐SmithMG , GracelyRH , BennettGJ . Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double‐blind comparison to alfentanil and placebo. Clinical Neuropharmacology1995;18:360‐8. ">Max 1995</a>). Meta‐analysis of these two trials demonstrated an additional 26% reduction in pain for opioid versus placebo (95% CI 17 to 35; P &lt; 0.00001) (<a href="./references#CD006146-fig-0004" title="">Analysis 1.2</a>), although the total number of participants (N = 19) was low. </p> </section> <section id="CD006146-sec-0068"> <h5 class="title">Sensitivity Analysis</h5> <p>Our two predetermined sensitivity analyses involved removing studies with fewer than 10 participants and removing cross‐over studies. Only one study involved in the meta‐analysis had fewer than 10 participants in a phase (<a href="./references#CD006146-bbs2-0020" title="MaxMB , Byas‐SmithMG , GracelyRH , BennettGJ . Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double‐blind comparison to alfentanil and placebo. Clinical Neuropharmacology1995;18:360‐8. ">Max 1995</a>). Removing this study had minimal effect on the point estimate and no effect on statistical significance. All of the short‐term studies involved in the meta‐analyses employed a cross‐over design, therefore sensitivity analysis by study design was not possible. </p> </section> </section> <section id="CD006146-sec-0069"> <h4 class="title">Intermediate‐term studies</h4> <p>The results from the intermediate‐term studies are summarized in <a href="./appendices#CD006146-sec-0101">Appendix 7</a>. </p> <p>Five trials from our updated search provided data on 385 participants with neuropathic pain treated with opioids (<a href="./references#CD006146-bbs2-0006" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199‐201. ">Frank 2008</a>; <a href="./references#CD006146-bbs2-0009" title="HannaM , O'BrienC , WilsonMC . Prolonged‐release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. European Journal of Pain2008;12:804‐13. ">Hanna 2008</a>; <a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a>; <a href="./references#CD006146-bbs2-0032" title="WuCL , AgarwalS , TellaPK , KlickB , ClarkMR , HaythornthwaiteJA , et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo‐controlled, crossover trial. Anesthesiology2008;109:289‐96. ">Wu 2008</a>; <a href="./references#CD006146-bbs2-0033" title="ZinCS , NissenLM , O'CallaghanJP , DuffullSB , SmithMT , MooreBJ . A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. Journal of Pain2010;11:462‐71. ">Zin 2010</a>)<b>.</b> The number per treatment group ranged from 29 to 169 (median 50). Three trials had a cross‐over design (<a href="./references#CD006146-bbs2-0006" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199‐201. ">Frank 2008</a>; <a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a>; <a href="./references#CD006146-bbs2-0032" title="WuCL , AgarwalS , TellaPK , KlickB , ClarkMR , HaythornthwaiteJA , et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo‐controlled, crossover trial. Anesthesiology2008;109:289‐96. ">Wu 2008</a>) and two had a parallel design (<a href="./references#CD006146-bbs2-0009" title="HannaM , O'BrienC , WilsonMC . Prolonged‐release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. European Journal of Pain2008;12:804‐13. ">Hanna 2008</a>; <a href="./references#CD006146-bbs2-0033" title="ZinCS , NissenLM , O'CallaghanJP , DuffullSB , SmithMT , MooreBJ . A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. Journal of Pain2010;11:462‐71. ">Zin 2010</a>)<b>.</b> </p> <p>When both the original and updated searches are combined, 14 trials provided data on 845 people treated with opioids. The number per treatment group ranged from 12 to 169 and the duration of treatment varied from eight days to 12 weeks. Nine trials had a cross‐over design and five had a parallel design. Five drugs were tested: morphine in six trials, oxycodone in five trials; methadone in one article comprising two trials; and levorphanol and dihydrocodeine in one trial each. Daily doses ranged from less than 5 mg to 300 mg of oral morphine equivalents, but were generally at the lower end of this range. Placebo was used as a control in all but two studies (<a href="./references#CD006146-bbs2-0006" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199‐201. ">Frank 2008</a>; <a href="./references#CD006146-bbs2-0025" title="RowbothamMC , TwillingL , DaviesPS , ReisnerL , TaylorK , MohrD . Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine2003;348:1223‐32. ">Rowbotham 2003</a>). Five trials, in addition to opioid and placebo, included at least one arm/phase where participants received an active control or combination of interventions: carbamazepine in one trial (<a href="./references#CD006146-bbs2-0010" title="HarkeH , GretenkortP , LadleifHU , RahmanS , HarkeO . The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained‐release morphine in patients pretreated with spinal cord stimulation: a double‐blinded randomized study. Anesthesia and Analgesia2001;92:488‐95. ">Harke 2001</a>), mexiletine (<a href="./references#CD006146-bbs2-0032" title="WuCL , AgarwalS , TellaPK , KlickB , ClarkMR , HaythornthwaiteJA , et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo‐controlled, crossover trial. Anesthesiology2008;109:289‐96. ">Wu 2008</a><b>),</b> the tricyclic antidepressants nortriptyline and desipramine (<a href="./references#CD006146-bbs2-0023" title="RajaSN , HaythornthwaiteJA , PappagalloM , ClarkMR , TravisonTG , SabeenS , et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo‐controlled trial. Neurology2002;59:1015‐21. ">Raja 2002</a>; <a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a>), and gabapentin (<a href="./references#CD006146-bbs2-0007" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352:1324‐34. ">Gilron 2005</a>)<b>.</b><a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a> also included a fourth arm of nortriptyline plus morphine. While many studies allowed participants to continue with any non‐opioid drug from their existing regimen, two trials specifically combined an active drug with the opioid and/or the placebo: pregabalin (<a href="./references#CD006146-bbs2-0033" title="ZinCS , NissenLM , O'CallaghanJP , DuffullSB , SmithMT , MooreBJ . A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. Journal of Pain2010;11:462‐71. ">Zin 2010</a>) and gabapentin (<a href="./references#CD006146-bbs2-0009" title="HannaM , O'BrienC , WilsonMC . Prolonged‐release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. European Journal of Pain2008;12:804‐13. ">Hanna 2008</a>). Two trials compared different dosages of an opioid: methadone (<a href="./references#CD006146-bbs2-0021" title="MorleyJS , BridsonJ , NashTP , MilesJB , WhiteS , MakinMK . Low‐dose methadone has an analgesic effect in neuropathic pain: a double‐blind randomized controlled crossover trial. Palliative Medicine2003;17:576‐87. ">Morley 2003</a>) and levorphanol (<a href="./references#CD006146-bbs2-0025" title="RowbothamMC , TwillingL , DaviesPS , ReisnerL , TaylorK , MohrD . Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine2003;348:1223‐32. ">Rowbotham 2003</a>). Eight trials enrolled participants with one specific pain syndrome: diabetic neuropathy (<a href="./references#CD006146-bbs2-0008" title="GimbelJS , RichardsP , PortenoyRK . Controlled‐release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology2003;60:927‐34. JensenMP , FriedmanM , BonzoD , RichardsP . The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clinical Journal of Pain2006;22:97‐103. ">Gimbel 2003</a>; <a href="./references#CD006146-bbs2-0009" title="HannaM , O'BrienC , WilsonMC . Prolonged‐release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. European Journal of Pain2008;12:804‐13. ">Hanna 2008</a>; <a href="./references#CD006146-bbs2-0029" title="WatsonCP , MoulinD , Watt‐WatsonJ , GordonA , EisenhofferJ . Controlled‐release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain2003;105:71‐8. ">Watson 2003</a>), PHN (<a href="./references#CD006146-bbs2-0023" title="RajaSN , HaythornthwaiteJA , PappagalloM , ClarkMR , TravisonTG , SabeenS , et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo‐controlled trial. Neurology2002;59:1015‐21. ">Raja 2002</a>; <a href="./references#CD006146-bbs2-0028" title="WatsonCP , BabulN . Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology1998;50:1837‐41. ">Watson 1998</a>), chronic lumbar root pain (<a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a><b>)</b> and postamputation pain (<a href="./references#CD006146-bbs2-0011" title="HuseE , LarbigW , FlorH , BirbaumerN . The effect of opioids on phantom limb pain and cortical reorganization. Pain2001;90:47‐55. ">Huse 2001</a>; <a href="./references#CD006146-bbs2-0032" title="WuCL , AgarwalS , TellaPK , KlickB , ClarkMR , HaythornthwaiteJA , et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo‐controlled, crossover trial. Anesthesiology2008;109:289‐96. ">Wu 2008</a>). The other studies enrolled people with neuropathic pain of diverse etiologies. </p> <section id="CD006146-sec-0070"> <h5 class="title">Meta‐analysis</h5> <section id="CD006146-sec-0071"> <h6 class="title">Primary outcome ‐ proportion of participants reporting ≥ 33% pain reduction from baseline or ≥ 50% pain reduction from baseline </h6> <p>The more recent studies presented data in a format that allowed us to analyze the number of participants with at least 33% and at least 50% pain relief. For the former, 208 of 367 participants (57%) receiving an opioid achieved at least 33% relief, versus 122 of 360 participants receiving placebo (34%) (<a href="./references#CD006146-fig-0005" title="">Analysis 2.1</a>). The overall point estimate of risk difference was 0.25 (95% CI 0.13 to 0.37, P &lt; 0.0001), translating to an NNTB of 4.0 (95% CI 2.7 to 7.7) There was significant heterogeneity (P = 0.02, I² = 63%), which was caused by the much larger risk differences (greater efficacy of opioids) in <a href="./references#CD006146-bbs2-0007" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352:1324‐34. ">Gilron 2005</a> and <a href="./references#CD006146-bbs2-0028" title="WatsonCP , BabulN . Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology1998;50:1837‐41. ">Watson 1998</a> in comparison with the other studies. When these studies were removed from the analysis, heterogeneity disappeared, leaving the overall point estimate of risk difference as 0.17 (95% CI: 0.09 to 0.25, P &lt; 0.0001), translating to an NNTB of 5.9 (95% CI 4.0 to 11.1). When number of participants achieving at least 50% pain relief was analyzed, the overall point estimate of risk difference was 0.17 (95% CI 0.02 to 0.33, P = 0.03) (<a href="./references#CD006146-fig-0006" title="">Analysis 2.2</a>), translating to an NNTB of 5.9 (3.0 to 50.0). Both the overall numbers of participants and the percentages achieving at least 50% pain relief were lower, with 72 of 154 (47%) participants receiving opioid versus 46 of 151 (30%) participants receiving placebo achieving at least 50% pain relief. One study (<a href="./references#CD006146-bbs2-0033" title="ZinCS , NissenLM , O'CallaghanJP , DuffullSB , SmithMT , MooreBJ . A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. Journal of Pain2010;11:462‐71. ">Zin 2010</a>) demonstrated a tendency towards a greater number of participants in the <i>placebo</i> group achieving at least 50% pain relief. When this study was removed, the overall point estimate of 0.22 (95% CI: 0.09 to 0.36) in favor of those receiving an opioid, translated to an NNTB of 4.5 (95% CI 2.8 to 11.1) . A smaller number of studies assessed the number of participants with at least 33% or at least 50% pain relief when comparing opioid with an active control (<a href="./references#CD006146-fig-0012" title="">Analysis 3.1</a>; <a href="./references#CD006146-fig-0013" title="">Analysis 3.2</a>). <a href="./references#CD006146-bbs2-0007" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352:1324‐34. ">Gilron 2005</a>; <a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a>; and <a href="./references#CD006146-bbs2-0032" title="WuCL , AgarwalS , TellaPK , KlickB , ClarkMR , HaythornthwaiteJA , et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo‐controlled, crossover trial. Anesthesiology2008;109:289‐96. ">Wu 2008</a> compared an opioid with gabapentin, a tricyclic antidepressant (nortriptyline), or an antiarrythmic (mexiletine), respectively. Only the last of these demonstrated a statistically significant difference between interventions, with morphine being superior to mexiletine when comparing the number of participants with both at least 33% pain relief (RD = 0.28, 95% CI: 0.08 to 0.48: NNTB = 3.6; 95% CI 2.1 to 12.5) and at least 50% pain relief (RD = 0.20, 95% CI: 0.01 to 0.39: NNTB = 5.0; 95% CI 2.6 to 100.0). Numbers of participants were low in this study, with 50 receiving morphine and 42 mexiletine. </p> </section> <section id="CD006146-sec-0072"> <h6 class="title">Secondary outcomes</h6> <section id="CD006146-sec-0073"> <p><b>Pain intensity post‐intervention</b></p> <p>Two studies from our updated search (<a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a>; <a href="./references#CD006146-bbs2-0032" title="WuCL , AgarwalS , TellaPK , KlickB , ClarkMR , HaythornthwaiteJA , et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo‐controlled, crossover trial. Anesthesiology2008;109:289‐96. ">Wu 2008</a>) added data to our 2005 analysis of pain intensity post‐intervention, comparing opioid and placebo (<a href="./references#CD006146-fig-0007" title="">Analysis 2.3</a>). Therefore, nine of the 14 studies provided data suitable for pooling. The meta‐analysis now includes 374 opioid‐treated and 351 placebo‐treated participants and shows the overall mean pain intensity to be 12 points lower in opioid‐treated participants than in those treated with placebo (95% CI ‐15 to ‐9; P &lt; 0.00001). The addition of the two studies from our updated search (<a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a>; <a href="./references#CD006146-bbs2-0032" title="WuCL , AgarwalS , TellaPK , KlickB , ClarkMR , HaythornthwaiteJA , et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo‐controlled, crossover trial. Anesthesiology2008;109:289‐96. ">Wu 2008</a>) made a negligible difference to the statistical significance or point estimate. Additionally, the same two studies added data to our analysis comparing mean VAS pain scores for opioids versus active controls (<a href="./references#CD006146-fig-0014" title="">Analysis 3.3</a>). As with comparisons of the number of participants with specified percentages of pain relief, only the comparison of morphine versus mexiletine (<a href="./references#CD006146-bbs2-0032" title="WuCL , AgarwalS , TellaPK , KlickB , ClarkMR , HaythornthwaiteJA , et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo‐controlled, crossover trial. Anesthesiology2008;109:289‐96. ">Wu 2008</a>) demonstrated statistically significant superiority: those receiving morphine had a 13 point lower pain intensity post‐intervention (P &lt; 0.0001, 95% CI; ‐19 to ‐7). Again, the total number of participants was low. </p> <p>Evoked pain data that we could meta‐analyze were reported in only two studies (<a href="./references#CD006146-bbs2-0028" title="WatsonCP , BabulN . Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology1998;50:1837‐41. ">Watson 1998</a>; <a href="./references#CD006146-bbs2-0029" title="WatsonCP , MoulinD , Watt‐WatsonJ , GordonA , EisenhofferJ . Controlled‐release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain2003;105:71‐8. ">Watson 2003</a>), with low overall numbers of participants. In both these trials oxycodone was significantly superior to placebo in reducing allodynia, categorized as 'skin pain' (<a href="./references#CD006146-fig-0008" title="">Analysis 2.4</a>). When the studies were combined statistically, participants receiving oxycodone had a 24 point lower score (95% CI: ‐34 to ‐13, P &lt; 0.0001) on a 0 ‐ 100 VAS. </p> <p>We found a dose‐dependent analgesic effect in two studies (<a href="./references#CD006146-bbs2-0021" title="MorleyJS , BridsonJ , NashTP , MilesJB , WhiteS , MakinMK . Low‐dose methadone has an analgesic effect in neuropathic pain: a double‐blind randomized controlled crossover trial. Palliative Medicine2003;17:576‐87. ">Morley 2003</a>; <a href="./references#CD006146-bbs2-0025" title="RowbothamMC , TwillingL , DaviesPS , ReisnerL , TaylorK , MohrD . Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine2003;348:1223‐32. ">Rowbotham 2003</a>) that included people with mixed neuropathies. In one (<a href="./references#CD006146-bbs2-0021" title="MorleyJS , BridsonJ , NashTP , MilesJB , WhiteS , MakinMK . Low‐dose methadone has an analgesic effect in neuropathic pain: a double‐blind randomized controlled crossover trial. Palliative Medicine2003;17:576‐87. ">Morley 2003</a>), 'low' and 'high' doses of methadone were each compared separately with placebo; the higher dose produced a greater effect than the lower dose. In the other study (<a href="./references#CD006146-bbs2-0025" title="RowbothamMC , TwillingL , DaviesPS , ReisnerL , TaylorK , MohrD . Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine2003;348:1223‐32. ">Rowbotham 2003</a>), a direct comparison showed that a higher dose of levorphanol produced a significantly greater analgesic effect than the lower dose. The use of different outcome measures in the two studies precluded the performance of a dose‐response meta‐analysis. </p> </section> <section id="CD006146-sec-0074"> <p><b>Quality of life and functioning</b></p> <p>Many of the trials measured the effects of opioids on emotional and physical functioning. However, because of the use of multiple measurement tools and differences in the way data were presented, only very limited meta‐analysis with low participant numbers was possible. Several studies compared opioid versus placebo for post‐intervention results in both the physical and mental health components of the Short Form‐36 (<a href="./references#CD006146-bbs2-0006" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199‐201. ">Frank 2008</a>; <a href="./references#CD006146-bbs2-0007" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352:1324‐34. ">Gilron 2005</a>; <a href="./references#CD006146-bbs2-0008" title="GimbelJS , RichardsP , PortenoyRK . Controlled‐release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology2003;60:927‐34. JensenMP , FriedmanM , BonzoD , RichardsP . The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clinical Journal of Pain2006;22:97‐103. ">Gimbel 2003</a>; <a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a>; <a href="./references#CD006146-bbs2-0029" title="WatsonCP , MoulinD , Watt‐WatsonJ , GordonA , EisenhofferJ . Controlled‐release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain2003;105:71‐8. ">Watson 2003</a>; <a href="./references#CD006146-bbs2-0033" title="ZinCS , NissenLM , O'CallaghanJP , DuffullSB , SmithMT , MooreBJ . A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. Journal of Pain2010;11:462‐71. ">Zin 2010</a>), including three studies from the updated search. The studies reported mixed results; however only two reported data in a format that enabled us to perform meta‐analysis (<a href="./references#CD006146-bbs2-0007" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352:1324‐34. ">Gilron 2005</a>; <a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a>). From these, only the sub scale 'bodily pain' demonstrated marginal superiority of opioid versus placebo, with those receiving morphine reporting a seven‐point improvement (95% CI: 0.1 to 13, <a href="./references#CD006146-fig-0009" title="">Analysis 2.5</a>). For those studies that also reported results for bodily pain, but in a format that we could not add to our meta‐analysis, two did not show an improvement of opioid over placebo (<a href="./references#CD006146-bbs2-0008" title="GimbelJS , RichardsP , PortenoyRK . Controlled‐release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology2003;60:927‐34. JensenMP , FriedmanM , BonzoD , RichardsP . The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clinical Journal of Pain2006;22:97‐103. ">Gimbel 2003</a>; <a href="./references#CD006146-bbs2-0033" title="ZinCS , NissenLM , O'CallaghanJP , DuffullSB , SmithMT , MooreBJ . A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. Journal of Pain2010;11:462‐71. ">Zin 2010</a>), whereas <a href="./references#CD006146-bbs2-0029" title="WatsonCP , MoulinD , Watt‐WatsonJ , GordonA , EisenhofferJ . Controlled‐release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain2003;105:71‐8. ">Watson 2003</a> did report superiority. When comparing opioid versus active control, neither <a href="./references#CD006146-bbs2-0007" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352:1324‐34. ">Gilron 2005</a> nor <a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a> demonstrated significant differences for any subscales, other than <a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a> reporting an 11‐point improvement in mental health for nortriptyline versus morphine (95% CI: 1 to 21) (<a href="./references#CD006146-fig-0015" title="">Analysis 3.4</a>). Two studies comparing opioid with placebo (<a href="./references#CD006146-bbs2-0007" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352:1324‐34. ">Gilron 2005</a>; <a href="./references#CD006146-bbs2-0008" title="GimbelJS , RichardsP , PortenoyRK . Controlled‐release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology2003;60:927‐34. JensenMP , FriedmanM , BonzoD , RichardsP . The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clinical Journal of Pain2006;22:97‐103. ">Gimbel 2003</a>) demonstrated improvements in several aspects of the Brief Pain Inventory, both physical and emotional, with the greatest improvement over placebo occurring in sleep, where those receiving an opioid had a 1.7 point (on an 11‐point scale) superiority over placebo (95% CI: ‐2.4 to ‐1.1, P &lt; 0.00001, <a href="./references#CD006146-fig-0010" title="">Analysis 2.6</a>). Emotional functioning was measured by several questionnaires, including the Beck Depression Inventory and the Profile of Mood States questionnaire. We were able to meta‐analyze data from the Beck Depression Inventory when comparing both opioid and placebo, and opioid with active controls. In both cases, meta‐analysis did not demonstrate statistical differences between interventions (<a href="./references#CD006146-fig-0011" title="">Analysis 2.7</a>; <a href="./references#CD006146-fig-0016" title="">Analysis 3.5</a>), although mean scores in all groups were in the minimal to mild depression range (<a href="./references#CD006146-bbs2-0089" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9:105‐21. ">Dworkin 2008</a>). Similarly, no improvement was noted in the Profile of Mood States scores of those with mixed neuropathies treated with two different dosages of levorphanol (<a href="./references#CD006146-bbs2-0025" title="RowbothamMC , TwillingL , DaviesPS , ReisnerL , TaylorK , MohrD . Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine2003;348:1223‐32. ">Rowbotham 2003</a>) nor in the Rand Mental Health Inventory completed by people with diabetic neuropathy following oxycodone treatment (<a href="./references#CD006146-bbs2-0008" title="GimbelJS , RichardsP , PortenoyRK . Controlled‐release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology2003;60:927‐34. JensenMP , FriedmanM , BonzoD , RichardsP . The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clinical Journal of Pain2006;22:97‐103. ">Gimbel 2003</a>). </p> </section> <section id="CD006146-sec-0075"> <p><b>Adverse events and withdrawals due to adverse events or lack of efficacy</b></p> <p>As with our 2005 review, we extracted data on the incidence of common opioid‐related adverse events from all intermediate‐term studies comparing opioids with placebo. In addition, for our updated review, we analyzed adverse events when comparing opioids with active controls and divided participant withdrawals into two categories: those due to adverse events and those due to lack of efficacy, although it could be argued that both denote failure of therapy. Finally, as noted above, we used a random‐effects model, as opposed to the fixed‐effect model employed in our original review. </p> <p>All but one of the intermediate‐term studies from our updated search contributed data for meta‐analysis: <a href="./references#CD006146-bbs2-0006" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199‐201. ">Frank 2008</a> counted each incidence of an adverse event, rather than the number of participants reporting. From our original review, <a href="./references#CD006146-bbs2-0011" title="HuseE , LarbigW , FlorH , BirbaumerN . The effect of opioids on phantom limb pain and cortical reorganization. Pain2001;90:47‐55. ">Huse 2001</a> reported adverse events on a VAS, precluding determination of the numbers of affected participants, and <a href="./references#CD006146-bbs2-0025" title="RowbothamMC , TwillingL , DaviesPS , ReisnerL , TaylorK , MohrD . Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine2003;348:1223‐32. ">Rowbotham 2003</a> compared two different doses of the opioid levorphanol; consequently their data could not be combined with other studies. The new studies approximately double the available participants ('N') for each analysis, increasing our confidence in their results. Although overall point estimates remained similar, the increased overall numbers meant that three of the comparisons for opioid versus placebo changed from non‐statistically significant to significant (dizziness, drowsiness and vomiting). </p> <p>The incidence of common adverse events in both opioid and placebo groups remained similar after including the new data: constipation was the most common (34% opioid versus 9% placebo: NNTH 4.0; 95% CI 3.0 to 5.6), followed by drowsiness (29% opioid versus 14% placebo: NNTH 7.1; 95% CI 4.0 to 33.3), nausea (27% opioid versus 9% placebo: NNTH 6.3; 95% CI 4.0 to 12.5), dizziness (22% opioid versus 8% placebo: NNTH 7.1; 95% CI 5.6 to 10.0), and vomiting (12% opioid versus 4% placebo: NNTH 12.5; 95% CI 6.7 to 100.0) (<a href="./references#CD006146-fig-0017" title="">Analysis 4.1</a>; <a href="./references#CD006146-fig-0018" title="">Analysis 4.2</a>; <a href="./references#CD006146-fig-0019" title="">Analysis 4.3</a>; <a href="./references#CD006146-fig-0020" title="">Analysis 4.4</a>; <a href="./references#CD006146-fig-0021" title="">Analysis 4.5</a>). Data on cognitive impairment as well as on other adverse events were insufficient to allow calculation of the NNTH. </p> <p>Our new analysis of adverse event rates for opioid versus active interventions generally demonstrated non‐statistically significant differences between treatments; however, both constipation (38% opioid versus 9% control: NNTH 3.4; 95% CI 2.6 to 4.8) and drowsiness (23% opioid versus 9% control: NNTH 7.7; 95% CI 5.0 to 16.7) occurred more frequently with opioids (<a href="./references#CD006146-fig-0024" title="">Analysis 5.1</a>; <a href="./references#CD006146-fig-0026" title="">Analysis 5.3</a>). </p> <p>When opioid therapy is initiated, recipients may abandon treatment because of either adverse events or lack of efficacy. In our updated analysis, more participants withdrew from opioid treatment due to adverse events than from placebo, with 55 (13%) of 435 participants in seven studies withdrawing during opioid therapy versus 18 (4%) of 432 receiving placebo (NNTH 12.5; 95% CI 8.3 to 25.0) (<a href="./references#CD006146-fig-0022" title="">Analysis 4.6</a>). Conversely, more participants receiving placebo withdrew due to lack of efficacy, with eight of 363 (2%) participants receiving opioid withdrawing versus 42 of 360 (12%) receiving placebo (NNTH ‐11.1; 95% CI ‐20.0 to ‐8.3) (<a href="./references#CD006146-fig-0023" title="">Analysis 4.7</a>). Only one study compared withdrawal rates between opioid and an active control, nortriptyline, and did not show a statistically significant difference in rates due to either adverse events or lack of efficacy (<a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a>). </p> <p>Both the Chi² and I² tests for each adverse event analyzed suggested that heterogeneity existed amongst results. This may have been due to genuine differences in event rates, differences in study populations, or as a result of authors using different measurements or thresholds for reporting adverse events. In most cases, removal of one outlying study from each analysis substantially reduced heterogeneity. </p> </section> </section> </section> <section id="CD006146-sec-0076"> <h5 class="title">Sensitivity Analysis</h5> <p>As with the short‐term studies, our two predetermined sensitivity analyses involved removing studies with fewer than 10 participants and removing cross‐over studies. None of the intermediate‐term studies had fewer than 10 participants in an individual arm or phase. All of the studies comparing opioid with active control in our meta‐analysis employed a cross‐over design; therefore sensitivity analysis of such studies was not possible. The majority of studies contributing data to our comparisons of opioid versus placebo also had a cross‐over design. Only five studies employed a parallel design (<a href="./references#CD006146-bbs2-0008" title="GimbelJS , RichardsP , PortenoyRK . Controlled‐release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology2003;60:927‐34. JensenMP , FriedmanM , BonzoD , RichardsP . The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clinical Journal of Pain2006;22:97‐103. ">Gimbel 2003</a>; <a href="./references#CD006146-bbs2-0009" title="HannaM , O'BrienC , WilsonMC . Prolonged‐release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. European Journal of Pain2008;12:804‐13. ">Hanna 2008</a>; <a href="./references#CD006146-bbs2-0010" title="HarkeH , GretenkortP , LadleifHU , RahmanS , HarkeO . The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained‐release morphine in patients pretreated with spinal cord stimulation: a double‐blinded randomized study. Anesthesia and Analgesia2001;92:488‐95. ">Harke 2001</a>; <a href="./references#CD006146-bbs2-0025" title="RowbothamMC , TwillingL , DaviesPS , ReisnerL , TaylorK , MohrD . Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine2003;348:1223‐32. ">Rowbotham 2003</a>; <a href="./references#CD006146-bbs2-0033" title="ZinCS , NissenLM , O'CallaghanJP , DuffullSB , SmithMT , MooreBJ . A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. Journal of Pain2010;11:462‐71. ">Zin 2010</a>). <a href="./references#CD006146-bbs2-0025" title="RowbothamMC , TwillingL , DaviesPS , ReisnerL , TaylorK , MohrD . Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine2003;348:1223‐32. ">Rowbotham 2003</a> did not contribute data to our analysis. In the few comparisons where there were sufficient numbers of both parallel and cross‐over studies, removal of cross‐over studies generally had only small effects on the point estimates of efficacy or safety, and in no cases did statistically significant overall estimates become non‐significant. Equally, the difference in overall estimates between cross‐over and parallel studies was small and did not consistently show more favorable results with cross‐over studies. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006146-sec-0077" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006146-sec-0077"></div> <section id="CD006146-sec-0078"> <h3 class="title" id="CD006146-sec-0078">Summary of main results</h3> <p>The results of this review can be divided into two categories according to the duration of included trials. </p> <section id="CD006146-sec-0079"> <h4 class="title">Short‐term studies</h4> <p>Short‐term trials demonstrated mixed results with respect to the analgesic efficacy of opioids. Our updated search did not yield any new studies suitable for statistical analysis. Although our meta‐analysis showed an overall mean difference in the last measured pain intensity for short‐term active treatment versus placebo of ‐16 points (on a 0 ‐ 100 visual analog scale (VAS)), the result should be interpreted with caution because it is based on only six of 17 studies (and only 90 of 392 participants). Thus, our conclusion regarding this category of studies has not changed from our previous meta‐analyses. </p> </section> <section id="CD006146-sec-0080"> <h4 class="title">Intermediate‐term studies</h4> <section id="CD006146-sec-0081"> <h5 class="title">Efficacy</h5> <p>In contrast, intermediate‐term trials demonstrated consistent opioid analgesic efficacy in reducing spontaneous neuropathic pain that was almost entirely statistically significant when results were pooled, although studies were small, mostly short, and potentially dealt inadequately with data once participants withdrew from treatment. Our updated review added data to our original analyses, increasing confidence in their findings, but also introduced new outcome analyses, i.e. number of participants with at least 33% and 50% reduction and assessments of functioning, which are considered clinically important in chronic pain (<a href="./references#CD006146-bbs2-0089" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9:105‐21. ">Dworkin 2008</a>). Intermediate‐term studies are more clinically relevant than short‐term studies because they assess the benefits and risks associated with opioid treatments for weeks to months, i.e. they reflect how opioids are administered for neuropathic pain in clinical practice. This part of the meta‐analysis was based on most of the available trials and included the majority of participants. Hence, we conclude that intermediate‐term opioid treatment has a beneficial effect over placebo for spontaneous neuropathic pain as measured by both number of participants with at least 33% and at least 50% pain relief and in mean differences in post‐intervention pain intensity. Opioids did not demonstrate improvement in many aspects of emotional or physical functioning, as measured by various validated questionnaires. This raises the concern that improvements in pain relief are not accompanied by similar improvements in activities of daily living or quality of life. It should be noted, however, that our meta‐analyses of functioning included few studies, with low overall numbers of participants. </p> <p>When comparing opioids with active controls, only the comparison of morphine with the rarely used antiarrythmic mexiletine demonstrated superiority of opioid (<a href="./references#CD006146-bbs2-0032" title="WuCL , AgarwalS , TellaPK , KlickB , ClarkMR , HaythornthwaiteJA , et al. Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo‐controlled, crossover trial. Anesthesiology2008;109:289‐96. ">Wu 2008</a>), with other comparisons not showing statistically significant differences between treatments. This may be due to opioids genuinely having similar efficacy to other interventions, or it may simply be a result of low participant numbers. Indirect comparisons with meta‐analyses of other treatments for neuropathic pain offer limited clarification. For example, <a href="./references#CD006146-bbs2-0105" title="MooreRA , WiffenPJ , DerryS , McQuayHJ . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2] ">Moore 2011</a> compared gabapentin with placebo for several similar efficacy outcomes. While the numbers needed to treat for an additional beneficial outcome (NNTBs) are similar for at least 50% pain relief and 33% pain relief (defined as 'moderate' relief in <a href="./references#CD006146-bbs2-0105" title="MooreRA , WiffenPJ , DerryS , McQuayHJ . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2] ">Moore 2011</a>), placebo rates are much higher in the opioid analyses. Equally, participants in the gabapentin analyses often required the maximum daily dose (3600 mg), whereas in the opioid studies a larger effect was achieved by a low to moderate dose of opioid. Moreover, the dose‐dependent analgesic effects shown in two of the opioid studies (<a href="./references#CD006146-bbs2-0021" title="MorleyJS , BridsonJ , NashTP , MilesJB , WhiteS , MakinMK . Low‐dose methadone has an analgesic effect in neuropathic pain: a double‐blind randomized controlled crossover trial. Palliative Medicine2003;17:576‐87. ">Morley 2003</a>; <a href="./references#CD006146-bbs2-0025" title="RowbothamMC , TwillingL , DaviesPS , ReisnerL , TaylorK , MohrD . Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine2003;348:1223‐32. ">Rowbotham 2003</a>) have not been confirmed by further trials; it is therefore unclear if high doses of opioids produce a greater magnitude of pain reduction in people with neuropathic pain. Thus, we are unable to confirm the commonly held belief that opioids have no ceiling effect in this population. This may be particularly important in light of recent concerns regarding mortality risk associated with high opioid dose regimens (<a href="./references#CD006146-bbs2-0093" title="GomesT , MamdaniMM , DhallaIA , PatersonM , JuurlinkDN . Opioid dose and drug‐related mortality in patients with nonmalignant pain. Archives of Internal Medicine2011;171:686‐91. ">Gomes 2011</a>). </p> </section> <section id="CD006146-sec-0082"> <h5 class="title">Safety</h5> <p>Our assessment of safety did not find data related to serious adverse events, including mortality, most likely because of the relative rarity of such events, especially with low‐to‐moderate doses of opioids. Instead, we were able to analyze data related to relatively common, widely identified opioid‐induced adverse events. Not surprisingly, and in agreement with our earlier review, many of the most commonly recognized opioid side effects occurred more frequently in those treated with opioid than with placebo. Conversely, there were few statistically significant differences between opioids and active controls, which may be due to controls having similar side‐effect profiles, or to the small participant numbers for each comparison. However, constipation and drowsiness did appear to occur more commonly. In placebo‐controlled studies, 13% of participants withdrew from opioid therapy due to adverse events, and 2% due to lack of efficacy. While these percentages are not particularly high, most of the study durations were less than eight weeks; therefore numbers may increase over longer periods. Additionally, the available randomized controlled trials (RCTs) do not clearly address the issues of addiction and abuse. The absence of any report of addictive behavior or abuse in any of the intermediate‐term trials may have several explanations. It is possible that the prevalence of these behaviors is indeed low (<a href="./references#CD006146-bbs2-0115" title="SullivanM , FerrellB . Ethical challenges in the management of chronic nonmalignant pain: negotiating through the cloud of doubt. Pain2005;6:2‐9. ">Sullivan 2005</a>). Alternatively, the duration of treatment in these studies may have been too short to allow such behaviors to develop. Furthermore, although not mentioned specifically as an exclusion criterion in all studies, it is reasonable to assume that the recruitment of people with active or potential abuse disorders (<a href="./references#CD006146-bbs2-0088" title="DunbarSA , KatzNP . Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: report of 20 cases. Journal of Pain and Symptom Management1996;11:163‐71. ">Dunbar 1996</a>) into such studies would routinely be avoided. The need to further assess the risk of abuse and addiction continues to be important. </p> </section> </section> </section> <section id="CD006146-sec-0083"> <h3 class="title" id="CD006146-sec-0083">Overall completeness and applicability of evidence</h3> <section id="CD006146-sec-0084"> <h4 class="title">Completeness</h4> <p>The included articles studied participants with a wide range of neuropathies, but predominately postherpetic neuralgia (PHN) and diabetic neuropathy. This reflects the distribution of neuropathic pain in the general population, with the exception that few studies included participants with back pain of neuropathic origin, which is thought to be the most common type of neuropathic pain (<a href="./references#CD006146-bbs2-0117" title="TorranceN , SmithBH . The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain2006;7:281‐9. ">Torrance 2006</a>). This may be due to the fact that it is often difficult to diagnose back pain as being purely neuropathic, with it frequently also having features of nociceptive pain. There were insufficient numbers of participants with individual neuropathies to perform a subanalysis of efficacy or safety. While our updated review added a substantial amount of data for each meta‐analysis, the overall numbers are still low for most comparisons. In particular, the inconsistency of reporting of outcomes related to functioning precludes our making firm conclusions. Many of the studies reported outcomes only on those participants completing the trial; therefore efficacy may have been over‐estimated. In those that performed an intention‐to‐treat (ITT) or modified ITT analysis, the most commonly used method of imputation was last observation carried forward (LOCF), which again may overestimate efficacy (<a href="./references#CD006146-bbs2-0106" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , WiffenP , et al. Estimate at your peril: Imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153:265‐8. ">Moore 2012</a>). None of the studies used baseline observation carried forward (BOCF). The short duration of many intermediate‐term studies is also a potential source of bias (<a href="./references#CD006146-bbs2-0103" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain2010;150:386‐9. '>Moore 2010a</a>). </p> </section> <section id="CD006146-sec-0085"> <h4 class="title">Applicability</h4> <p>Several points deserve consideration in terms of applicability of the evidence.</p> <p>First, the fact that short‐term trials, in contrast to the intermediate‐term trials, yielded inconsistent efficacy results suggests that short‐term opioid administration is unlikely to serve as a useful predictive tool when initiating a trial of opioid therapy in people with neuropathic pain. </p> <p>Second, the NNTB results further confirm that opioids reduce various forms of neuropathic pain and are relatively safe, and therefore indicate that opioids at low‐to‐moderate doses are suitable for use over periods of weeks to months in the treatment of neuropathic pain. However, despite the common use of NNTB values to compare relative efficacy of different treatments, especially when head‐to‐head comparative trials are relatively scarce, their validity has been questioned for reasons such as differences in trial designs, exclusion of non‐placebo‐controlled trials, dichotomization of data, and strict and not necessarily clinically relevant cut‐off points (i.e. 50% pain relief) (<a href="./references#CD006146-bbs2-0092" title="FinnerupNB , SindrupSH , JensenTS . The evidence for pharmacological treatment of neuropathic pain. Pain2010;150:573‐81. ">Finnerup 2010</a>). </p> <p>Third, the use of a single dimension for assessment of efficacy of analgesic treatments is problematic in any form of chronic pain, which is a multi‐dimensional phenomenon. This becomes even more problematic in neuropathic pain, where even a single etiological syndrome (e.g. PHN) typically differs considerably from one patient to another in term of its clinical representation. For that reason the use of additional outcome measures rather than a single pain intensity or pain relief method have been recommended (<a href="./references#CD006146-bbs2-0119" title="WittinkH , CarrDB , Eds . Pain management: Evidence, outcomes and quality of life. A sourcebook. Amsterdam, The Netherlands: Elsevier, 2005. ">Wittink 2005</a>). Unfortunately, consistent improvement in specific features of neuropathic pain (e.g. evoked pain), in emotional or physical aspects of functioning, or in health‐related quality of life could not be demonstrated in the present review. </p> <p>Fourth, the debate regarding the differential efficacy of opioids for central versus peripheral neuropathic pain (<a href="./references#CD006146-bbs2-0078" title="BallantyneJC , MaoJ . Opioid therapy for chronic pain. New England Journal of Medicine2003;349:1943‐53. ">Ballantyne 2003</a>; <a href="./references#CD006146-bbs2-0083" title="CanaveroS , BonicalziV . Chronic neuropathic pain. New England Journal of Medicine2003;348:2688‐9. ">Canavero 2003</a>; <a href="./references#CD006146-bbs2-0086" title="DellemijnP . Are opioids effective in relieving neuropathic pain?. Pain1999;80:453‐62. ">Dellemijn 1999</a>; <a href="./references#CD006146-bbs2-0100" title="McQuayHJ . Opioid use in chronic pain. Acta Anaesthesiologica Scandinavica1997;41:175‐83. ">McQuay 1997</a>; <a href="./references#CD006146-bbs2-0108" title="NicholsonBD . Evaluation and treatment of central pain syndromes. Neurology2004;62 (Suppl 2):S30‐6. ">Nicholson 2004</a>) has not been resolved by our study. Results of the included studies varied considerably and the meta‐analyses could not include all relevant studies. Despite limited data, the meta‐analyses showed similar opioid responsiveness for pain of central and peripheral etiologies. </p> <p>Fifth, although a dose‐dependent analgesic effect was found in two studies, the dose ranges tested are still in the low‐intermediate range and do not necessarily reflect clinical practice in some countries (e.g. the USA). This, along with increasing concerns about opioid toxicity, especially at higher dose ranges (greater than the daily equivalent of 200 mg of oral morphine), does not support the use of high doses of opioids for the relief of neuropathic pain. </p> <p>Lastly, this review also included a quantitative analysis of common opioid‐related adverse effects. Although the analysis is based on a relatively large number of participants with neuropathic pain, those enrolled in clinical trials may not be representative of the broader patient population seen in clinical practice. Enrolled participants have met inclusion criteria, and their willingness to enter a clinical trial suggests that they may have a higher adherence profile compared with those who are not enrolled. </p> </section> </section> <section id="CD006146-sec-0086"> <h3 class="title" id="CD006146-sec-0086">Quality of the evidence</h3> <p>The quality of evidence improved somewhat with those articles included in our updated search. Many more of the newer studies reported outcomes considered to be clinically relevant, such as numbers of participants with at least 50% pain relief, and in a format that allowed us to perform meta‐analysis (<a href="./references#CD006146-bbs2-0089" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9:105‐21. ">Dworkin 2008</a>). Additionally, the risk of bias for each domain, while low overall, was generally lower in newer studies. </p> </section> <section id="CD006146-sec-0087"> <h3 class="title" id="CD006146-sec-0087">Potential biases in the review process</h3> <p>We believe the search methodology used here to be unbiased, and the selection criteria relevant to the nature of neuropathic pain. However, two aspects of our review methodology have the potential to introduce bias to our analyses. First, we included studies of less than 12 weeks duration. While we included 'short‐term' studies purely for 'proof of concept', even amongst our 'intermediate‐term' studies only one (<a href="./references#CD006146-bbs2-0009" title="HannaM , O'BrienC , WilsonMC . Prolonged‐release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. European Journal of Pain2008;12:804‐13. ">Hanna 2008</a>) was conducted over 12 weeks. Studies of less than 12 weeks duration may overestimate treatment efficacy (<a href="./references#CD006146-bbs2-0103" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain2010;150:386‐9. '>Moore 2010a</a>). Given the dearth of long‐term studies, we adopted a 'best available evidence' approach, and anticipate that future studies will have longer durations, allowing us to better assess the efficacy and safety of opioids administered over clinically relevant time periods. </p> <p>Second, we analyzed data from cross‐over studies in the same manner as that from parallel studies. This approach may give rise to a unit‐of‐analysis error (<a href="./references#CD006146-bbs2-0095" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). However, as discussed (<a href="#CD006146-sec-0064">Effects of interventions</a>) we performed a sensitivity analysis where cross‐over studies were removed from meta‐analyses and found negligible differences in estimates of effect for either efficacy or safety. </p> </section> <section id="CD006146-sec-0088"> <h3 class="title" id="CD006146-sec-0088">Agreements and disagreements with other studies or reviews</h3> <p>Most recent guidelines on the pharmacotherapy of neuropathic pain are in agreement with the results of the present review and recommend the use of opioids, typically as second‐ or third‐line treatment options (<a href="./references#CD006146-bbs2-0077" title="AttalN , CruccuG , BaronR , HaanpääM , HanssonP , JensenTS , et al. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology2010;17:1113‐e88. ">Attal 2010</a>; <a href="./references#CD006146-bbs2-0090" title="DworkinRH , O'ConnorAB . Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clinic Proceedings2010;83:S3‐14. ">Dworkin 2010</a>; <a href="./references#CD006146-bbs2-0107" title="MoulinDE , ClarkAJ , GilronI , WareMA , WatsonCP , SessleBJ , et al. Canadian Pain Society. Pharmacological management of chronic neuropathic pain ‐ consensus statement and guidelines from the Canadian Pain Society. Pain Research and Management2007;12:13‐21. ">Moulin 2007</a>; <a href="./references#CD006146-bbs2-0111" title="PergolizziJ , BögerRH , BuddK , DahanA , ErdineS , HansG , et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Practice2008;8:287‐313. ">Pergolizzi 2008</a>). </p> <p>A systematic review of the evidence for pharmacological treatment of neuropathic pain (<a href="./references#CD006146-bbs2-0092" title="FinnerupNB , SindrupSH , JensenTS . The evidence for pharmacological treatment of neuropathic pain. Pain2010;150:573‐81. ">Finnerup 2010</a>) also found that opioids have a consistent efficacy in neuropathic pain. Notably, the NNTBs for achieving meaningful pain relief in several neuropathic pain conditions (i.e. painful polyneuropathy, postherpetic neuralgia, peripheral nerve injury and mixed neuropathic pain) varied from 2.1 to 5.1 and were slightly lower than the NNTBs found in the present review. The differences in findings occurred for several reasons. First, we excluded studies with tramadol. Second, we had two additional studies in our NNTB analysis (<a href="./references#CD006146-bbs2-0015" title="KhoromiS , CuiL , NackersL , MaxMB . Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain2007;130:66‐75. ">Khoromi 2007</a>; <a href="./references#CD006146-bbs2-0033" title="ZinCS , NissenLM , O'CallaghanJP , DuffullSB , SmithMT , MooreBJ . A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. Journal of Pain2010;11:462‐71. ">Zin 2010</a>). Third, <a href="./references#CD006146-bbs2-0092" title="FinnerupNB , SindrupSH , JensenTS . The evidence for pharmacological treatment of neuropathic pain. Pain2010;150:573‐81. ">Finnerup 2010</a> combined results for participants with at least 33% and at least 50% pain relief, whereas we analyzed these outcomes separately. Last, and perhaps most importantly, they performed meta‐analysis separately for each neuropathic pain syndrome. We combined data as we considered numbers of participants for each syndrome to be insufficient for subanalysis. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006146-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006146-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/full#CD006146-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006146-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/full#CD006146-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Short‐term Efficacy Studies: opioid vs placebo, Outcome 1 Pain intensity post‐opioid/placebo." data-id="CD006146-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Short‐term Efficacy Studies: opioid vs placebo, Outcome 1 Pain intensity post‐opioid/placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Short‐term Efficacy Studies: opioid vs placebo, Outcome 2 % Pain reduction post‐opioid/placebo." data-id="CD006146-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Short‐term Efficacy Studies: opioid vs placebo, Outcome 2 % Pain reduction post‐opioid/placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermediate‐term Efficacy Studies: Opioid vs. Placebo, Outcome 1 Number of participants with at least 33% pain relief." data-id="CD006146-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Intermediate‐term Efficacy Studies: Opioid vs. Placebo, Outcome 1 Number of participants with at least 33% pain relief. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermediate‐term Efficacy Studies: Opioid vs. Placebo, Outcome 2 Number of participants with at least 50% pain relief." data-id="CD006146-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Intermediate‐term Efficacy Studies: Opioid vs. Placebo, Outcome 2 Number of participants with at least 50% pain relief. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermediate‐term Efficacy Studies: Opioid vs. Placebo, Outcome 3 Pain intensity post‐opioid/placebo." data-id="CD006146-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Intermediate‐term Efficacy Studies: Opioid vs. Placebo, Outcome 3 Pain intensity post‐opioid/placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermediate‐term Efficacy Studies: Opioid vs. Placebo, Outcome 4 Evoked pain intensity post‐opioid/placebo." data-id="CD006146-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Intermediate‐term Efficacy Studies: Opioid vs. Placebo, Outcome 4 Evoked pain intensity post‐opioid/placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermediate‐term Efficacy Studies: Opioid vs. Placebo, Outcome 5 SF‐36 Health Survey." data-id="CD006146-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Intermediate‐term Efficacy Studies: Opioid vs. Placebo, Outcome 5 SF‐36 Health Survey. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermediate‐term Efficacy Studies: Opioid vs. Placebo, Outcome 6 Brief Pain Inventory: Pain Interference items." data-id="CD006146-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Intermediate‐term Efficacy Studies: Opioid vs. Placebo, Outcome 6 Brief Pain Inventory: Pain Interference items. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermediate‐term Efficacy Studies: Opioid vs. Placebo, Outcome 7 Beck Depression Inventory." data-id="CD006146-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Intermediate‐term Efficacy Studies: Opioid vs. Placebo, Outcome 7 Beck Depression Inventory. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intermediate‐term Efficacy Studies: opioid vs active control, Outcome 1 Number of participants with at least 33% pain relief." data-id="CD006146-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Intermediate‐term Efficacy Studies: opioid vs active control, Outcome 1 Number of participants with at least 33% pain relief. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intermediate‐term Efficacy Studies: opioid vs active control, Outcome 2 Number of participants with at least 50% pain relief." data-id="CD006146-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Intermediate‐term Efficacy Studies: opioid vs active control, Outcome 2 Number of participants with at least 50% pain relief. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intermediate‐term Efficacy Studies: opioid vs active control, Outcome 3 Pain intensity post‐opioid/active control." data-id="CD006146-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Intermediate‐term Efficacy Studies: opioid vs active control, Outcome 3 Pain intensity post‐opioid/active control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intermediate‐term Efficacy Studies: opioid vs active control, Outcome 4 SF‐36 Health Survey." data-id="CD006146-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Intermediate‐term Efficacy Studies: opioid vs active control, Outcome 4 SF‐36 Health Survey. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intermediate‐term Efficacy Studies: opioid vs active control, Outcome 5 Beck Depression Inventory." data-id="CD006146-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Intermediate‐term Efficacy Studies: opioid vs active control, Outcome 5 Beck Depression Inventory. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse Events from Intermediate‐term Studies: opioid vs placebo, Outcome 1 Participants reporting constipation." data-id="CD006146-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Adverse Events from Intermediate‐term Studies: opioid vs placebo, Outcome 1 Participants reporting constipation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse Events from Intermediate‐term Studies: opioid vs placebo, Outcome 2 Participants reporting dizziness." data-id="CD006146-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Adverse Events from Intermediate‐term Studies: opioid vs placebo, Outcome 2 Participants reporting dizziness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse Events from Intermediate‐term Studies: opioid vs placebo, Outcome 3 Participants reporting drowsiness/somnolence." data-id="CD006146-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Adverse Events from Intermediate‐term Studies: opioid vs placebo, Outcome 3 Participants reporting drowsiness/somnolence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse Events from Intermediate‐term Studies: opioid vs placebo, Outcome 4 Participants reporting nausea." data-id="CD006146-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Adverse Events from Intermediate‐term Studies: opioid vs placebo, Outcome 4 Participants reporting nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse Events from Intermediate‐term Studies: opioid vs placebo, Outcome 5 Participants reporting vomiting." data-id="CD006146-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Adverse Events from Intermediate‐term Studies: opioid vs placebo, Outcome 5 Participants reporting vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse Events from Intermediate‐term Studies: opioid vs placebo, Outcome 6 Particpants withdrawing due to adverse events." data-id="CD006146-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Adverse Events from Intermediate‐term Studies: opioid vs placebo, Outcome 6 Particpants withdrawing due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Adverse Events from Intermediate‐term Studies: opioid vs placebo, Outcome 7 Participants withdrawing due to lack of efficacy." data-id="CD006146-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Adverse Events from Intermediate‐term Studies: opioid vs placebo, Outcome 7 Participants withdrawing due to lack of efficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse Events from Intermediate‐term Studies: opioid vs active control, Outcome 1 Participants reporting constipation." data-id="CD006146-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Adverse Events from Intermediate‐term Studies: opioid vs active control, Outcome 1 Participants reporting constipation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse Events from Intermediate‐term Studies: opioid vs active control, Outcome 2 Participants reporting dizziness." data-id="CD006146-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Adverse Events from Intermediate‐term Studies: opioid vs active control, Outcome 2 Participants reporting dizziness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse Events from Intermediate‐term Studies: opioid vs active control, Outcome 3 Participants reporting drowsiness/somnolence." data-id="CD006146-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Adverse Events from Intermediate‐term Studies: opioid vs active control, Outcome 3 Participants reporting drowsiness/somnolence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse Events from Intermediate‐term Studies: opioid vs active control, Outcome 4 Participants reporting nausea." data-id="CD006146-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Adverse Events from Intermediate‐term Studies: opioid vs active control, Outcome 4 Participants reporting nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse Events from Intermediate‐term Studies: opioid vs active control, Outcome 5 Participants reporting vomiting." data-id="CD006146-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Adverse Events from Intermediate‐term Studies: opioid vs active control, Outcome 5 Participants reporting vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse Events from Intermediate‐term Studies: opioid vs active control, Outcome 6 Participants withdrawing due to adverse events." data-id="CD006146-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Adverse Events from Intermediate‐term Studies: opioid vs active control, Outcome 6 Participants withdrawing due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006146-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/urn:x-wiley:14651858:media:CD006146:CD006146-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_t/tCD006146-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Adverse Events from Intermediate‐term Studies: opioid vs active control, Outcome 7 Participants withdrawing due to lack of efficacy." data-id="CD006146-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Adverse Events from Intermediate‐term Studies: opioid vs active control, Outcome 7 Participants withdrawing due to lack of efficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/media/CDSR/CD006146/image_n/nCD006146-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD006146-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Short‐term Efficacy Studies: opioid vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain intensity post‐opioid/placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.81 [‐22.54, ‐9.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Peripheral Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.01 [‐22.97, ‐7.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Central Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐17.81 [‐30.48, ‐5.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 % Pain reduction post‐opioid/placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.78 [16.91, 34.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Short‐term Efficacy Studies: opioid vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006146-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Intermediate‐term Efficacy Studies: Opioid vs. Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants with at least 33% pain relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.13, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants with at least 50% pain relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.02, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Pain intensity post‐opioid/placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.01 [‐15.40, ‐8.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Evoked pain intensity post‐opioid/placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐23.73 [‐34.50, ‐12.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 SF‐36 Health Survey <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Physical functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [‐5.46, 11.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Role‐physical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.62 [‐7.73, 26.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Bodily pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.78 [0.08, 13.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 General health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐8.08, 6.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Vitality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [‐5.82, 9.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.40 [‐5.09, 11.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Role‐emotional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.97 [‐5.06, 21.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [‐3.05, 9.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Brief Pain Inventory: Pain Interference items <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 General activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.91 [‐1.67, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Mood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐1.31, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Walking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐1.28, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Normal work</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.82 [‐1.59, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Social relations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐1.25, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.74 [‐2.42, ‐1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Enjoyment of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.18 [‐1.91, ‐0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Beck Depression Inventory <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐2.29, 2.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Intermediate‐term Efficacy Studies: Opioid vs. Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006146-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intermediate‐term Efficacy Studies: opioid vs active control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants with at least 33% pain relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.04, 0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 opioid vs gabapentin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.01, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 opioid vs tricyclic antidepressant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.22, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 opioid vs antiarrythmic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.08, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants with at least 50% pain relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.20, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 opioid vs tricyclic antidepressant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.30, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 opioid vs antiarrythmic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Pain intensity post‐opioid/active control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.19 [‐13.13, ‐1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 opioid vs gabapentin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.0 [‐14.40, 4.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 opioid vs tricyclic antidepressant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐13.48, 6.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 opioid vs antiarrythmic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.0 [‐19.12, ‐6.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 SF‐36 Health Survey <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Physical functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.09 [‐13.81, 3.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Role‐physical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.38 [‐19.05, 8.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Bodily pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.11 [‐9.91, 3.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 General health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.44 [‐11.75, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Vitality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.60 [‐13.63, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.04 [‐14.44, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Role‐emotional</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.39 [‐19.37, 6.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.24 [‐14.06, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Beck Depression Inventory <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐0.38, 3.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 opioid vs gabapentin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐2.46, 3.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 opioid vs tricyclic antidepressant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [‐0.14, 4.49]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intermediate‐term Efficacy Studies: opioid vs active control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006146-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Adverse Events from Intermediate‐term Studies: opioid vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants reporting constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.18, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants reporting dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.10, 0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants reporting drowsiness/somnolence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.03, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Participants reporting nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.08, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Participants reporting vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.01, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Particpants withdrawing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.04, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Participants withdrawing due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.12, ‐0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Adverse Events from Intermediate‐term Studies: opioid vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006146-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Adverse Events from Intermediate‐term Studies: opioid vs active control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants reporting constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.21, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants reporting dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.05, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants reporting drowsiness/somnolence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.06, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Participants reporting nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.01, 0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Participants reporting vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.04, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Participants withdrawing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.06, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Participants withdrawing due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.05, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Adverse Events from Intermediate‐term Studies: opioid vs active control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006146.pub2/references#CD006146-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006146.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006146-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006146-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD006146-note-0001">Hrvatski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006146-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006146\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006146\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006146\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006146\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006146\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006146.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006146.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006146.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006146.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006146.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717530849"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006146.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717530853"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006146.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dba2d9ec69371',t:'MTc0MDcxNzUzMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 